{
    "id": "dbpedia_8094_0",
    "rank": 52,
    "data": {
        "url": "https://patents.google.com/patent/WO2018015677A1/en",
        "read_more_link": "",
        "language": "en",
        "title": "WO2018015677A1 - Method for the resolution of baclofen salts - Google Patents",
        "top_image": "https://patentimages.storage.googleapis.com/e8/48/48/49bec52e00d84c/imgf000002_0001.png",
        "meta_img": "",
        "images": [
            "https://patentimages.storage.googleapis.com/e8/48/48/49bec52e00d84c/imgf000002_0001.png",
            "https://patentimages.storage.googleapis.com/e8/48/48/49bec52e00d84c/imgf000002_0001.png",
            "https://patentimages.storage.googleapis.com/ce/4c/cf/fdf3667b258c46/imgf000002_0002.png",
            "https://patentimages.storage.googleapis.com/ce/4c/cf/fdf3667b258c46/imgf000002_0002.png",
            "https://patentimages.storage.googleapis.com/6a/57/d5/5c5523b12cf0be/imgf000002_0003.png",
            "https://patentimages.storage.googleapis.com/6a/57/d5/5c5523b12cf0be/imgf000002_0003.png",
            "https://patentimages.storage.googleapis.com/64/d9/19/c41e7dfab9b958/imgf000003_0001.png",
            "https://patentimages.storage.googleapis.com/64/d9/19/c41e7dfab9b958/imgf000003_0001.png",
            "https://patentimages.storage.googleapis.com/45/d5/42/cbe91e82b9ce89/imgf000003_0002.png",
            "https://patentimages.storage.googleapis.com/45/d5/42/cbe91e82b9ce89/imgf000003_0002.png",
            "https://patentimages.storage.googleapis.com/99/95/40/edf863ee127ff7/imgf000003_0003.png",
            "https://patentimages.storage.googleapis.com/99/95/40/edf863ee127ff7/imgf000003_0003.png",
            "https://patentimages.storage.googleapis.com/72/72/8d/e2a8dd30f4a372/imgf000007_0001.png",
            "https://patentimages.storage.googleapis.com/72/72/8d/e2a8dd30f4a372/imgf000007_0001.png",
            "https://patentimages.storage.googleapis.com/0a/af/b5/0d67c434492416/imgf000015_0001.png",
            "https://patentimages.storage.googleapis.com/0a/af/b5/0d67c434492416/imgf000015_0001.png",
            "https://patentimages.storage.googleapis.com/45/f3/1a/c8481ff9821f39/imgf000015_0002.png",
            "https://patentimages.storage.googleapis.com/45/f3/1a/c8481ff9821f39/imgf000015_0002.png",
            "https://patentimages.storage.googleapis.com/eb/76/4a/fb10dbc62c9fa6/imgf000016_0001.png",
            "https://patentimages.storage.googleapis.com/eb/76/4a/fb10dbc62c9fa6/imgf000016_0001.png",
            "https://patentimages.storage.googleapis.com/f0/a4/ec/2a131cb9264e28/imgf000018_0001.png",
            "https://patentimages.storage.googleapis.com/f0/a4/ec/2a131cb9264e28/imgf000018_0001.png",
            "https://patentimages.storage.googleapis.com/ed/47/60/857d0249a70958/imgf000019_0001.png",
            "https://patentimages.storage.googleapis.com/ed/47/60/857d0249a70958/imgf000019_0001.png",
            "https://patentimages.storage.googleapis.com/dd/ae/23/5b63cec13b5c3f/imgf000021_0001.png",
            "https://patentimages.storage.googleapis.com/dd/ae/23/5b63cec13b5c3f/imgf000021_0001.png",
            "https://patentimages.storage.googleapis.com/78/3e/df/39dda9e6c62a59/imgf000023_0001.png",
            "https://patentimages.storage.googleapis.com/78/3e/df/39dda9e6c62a59/imgf000023_0001.png",
            "https://patentimages.storage.googleapis.com/75/d6/65/c42dcca2817625/imgf000023_0002.png",
            "https://patentimages.storage.googleapis.com/75/d6/65/c42dcca2817625/imgf000023_0002.png",
            "https://patentimages.storage.googleapis.com/ad/e4/79/386d11270a5fc5/imgf000025_0001.png",
            "https://patentimages.storage.googleapis.com/ad/e4/79/386d11270a5fc5/imgf000025_0001.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2016-07-22T00:00:00",
        "summary": "",
        "meta_description": "The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(-) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/WO2018015677A1/en",
        "text": "PROCÃDÃ DE DÃDOUBLEMENT DE SELS DE BACLOFÃNE Â PROCESS FOR DEDOLDING BACLOFEN SALTS\n\nDOMAINE TECHNIQUE TECHNICAL AREA\n\nLa prÃ©sente invention concerne le domaine du dÃ©doublement de composÃ©s chiraux existant sous la forme de deux antipodes optiques (Ã©nantiomÃ¨res), comme le BaclofÃ¨ne. Â The present invention relates to the domain of the resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen.\n\nPlus particuliÃ¨rement, l'invention concerne la prÃ©paration des Ã©nantiomÃ¨res purs (R)(-) BaclofÃ¨ne et S(+)BaclofÃ¨ne, de nomenclature chimique acide (R)-4-amino-3-(4-chlorophÃ©nyl)- butanoÃ¯que et acide (S)-4-amino-3-(4-chlorophÃ©nyl)-butanoÃ¯que et de leur sel d'hydrogÃ©nomalÃ©ate. Â More particularly, the invention relates to the preparation of pure enantiomers (R) (-) Baclofen and S (+) Baclofen, of chemical nomenclature acid (R) -4-amino-3- (4-chlorophenyl) butanoic acid ( S) -4-Amino-3- (4-chlorophenyl) -butanoic acid and their hydrogen maleate salt.\n\nTout spÃ©cialement, la prÃ©sente invention concerne le dÃ©doublement des sels d'hydrogÃ©nomalÃ©ate du BaclofÃ¨ne racÃ©mique par cristallisation prÃ©fÃ©rentielle et notamment par le procÃ©dÃ© AS3PC (cristallisation prÃ©fÃ©rentielle polythermique programmÃ©e et auto-ensemencÃ©e) ou le procÃ©dÃ© ASPreCISE (cristallisation prÃ©fÃ©rentielle auto-ensemencÃ©e induite par Ã©vaporation de solvant). Â Most particularly, the present invention relates to the resolution of the hydrogen maleate salts of racemic Baclofen by preferential crystallization and in particular by the AS3PC method (preferred polythermic preferential crystallization and self-seeded) or the ASPreCISE process (preferential crystallization self-seeded induced by evaporation of solvent).\n\nARRIÃRE-PLAN DE L'INVENTION BACKGROUND OF THE INVENTION\n\nLe BaclofÃ¨ne racÃ©mique est reprÃ©sentÃ© par la formule gÃ©nÃ©rale (I) ci-dessous : Â Racemic Baclofen is represented by the following general formula (I):\n\nL'Ã©nantiomÃ¨re pur (R)(-)BaclofÃ¨ne est reprÃ©sentÃ© par la formule gÃ©nÃ©rale (II) ci-dessous : Â The pure enantiomer (R) (-) Baclofen is represented by the general formula (II) below:\n\nL'Ã©nantiomÃ¨re pur (S)(-)BaclofÃ¨ne est reprÃ©sentÃ© par la formule gÃ©nÃ©rale (III) ci-dessous : The pure enantiomer (S) (-) Baclofen is represented by the general formula (III) below:\n\nLe BaclofÃ¨ne, Ã©galement connu sous le nom de LiorÃ©sal, est un mÃ©dicament utilisÃ© comme myorelaxant pour traiter des contractures douloureuses qui accompagnent la sclÃ©rose en plaques et certaines paralysies. Â Baclofen, also known as Lioresal, is a drug used as a muscle relaxant to treat painful contractures that accompany multiple sclerosis and certain paralysis.\n\nEn France, l'Agence Nationale de SÃ©curitÃ© du MÃ©dicament et des Produits de SantÃ© (ANSM) a rÃ©cemment dÃ©livrÃ© une recommandation temporaire d'utilisation du BaclofÃ¨ne pour le traitement de la dÃ©pendance alcoolique. Â In France, the National Agency for the Safety of Medicines and Health Products (ANSM) has recently issued a temporary recommendation for the use of Baclofen for the treatment of alcohol dependence.\n\nDans son utilisation thÃ©rapeutique actuelle, cette molÃ©cule est administrÃ©e sous forme d'un mÃ©lange racÃ©mique. L'Ã©nantiomÃ¨re R(-) Ã©tant trois fois plus actif que l'Ã©nantiomÃ¨re S(+), il apparaÃ®t intÃ©ressant, surtout pour de longs traitements, de ne prescrire que la seule configuration absolue R(-) la plus active. De la sorte, il y aura moins de sous-produits dans l'organisme et le dosage pourra Ãªtre rÃ©duit tout en prÃ©servant le bÃ©nÃ©fice de l'activitÃ©. In its current therapeutic use, this molecule is administered in the form of a racemic mixture. Since the R (-) enantiomer is three times more active than the S (+) enantiomer, it seems interesting, especially for long treatments, to prescribe only the absolute configuration. R (-) the most active. In this way, there will be fewer by-products in the body and the dosage can be reduced while preserving the benefit of the activity.\n\nPour produire la forme R(-), les mÃ©thodes dÃ©crites dans la littÃ©rature mettent en Åuvre soit une synthÃ¨se asymÃ©trique Ã partir d'un mÃ©lange racÃ©mique ou d'un composÃ© prochiral avec des catalyseurs, soit une synthÃ¨se Ã©nantiosÃ©lective Ã partir d'un rÃ©actif chiral. Â To produce the R (-) form, the methods described in the literature implement either an asymmetric synthesis from a racemic mixture or a prochiral compound with catalysts, or an enantioselective synthesis from a chiral reagent .\n\nPar exemple, il est possible d'utiliser des catalyseurs enzymatique, comme des bactÃ©ries de type Rhodococcus sp. , tel que dÃ©crit dans M.X. Wang, S. M. Zhao, Tetrahedron Lett. 2002, 43, 6617-6620, pour accÃ©der au R(-)BaclofÃ¨ne selon le schÃ©ma suivant : Â For example, it is possible to use enzymatic catalysts, such as Rhodococcus sp. as described in M.X. Wang, S. M. Zhao, Tetrahedron Lett. 2002, 43, 6617-6620, to access R (-) Baclofen according to the following scheme:\n\nracÃ©mique acide (R) amide (S) R(-)BaclofÃ¨ne Â racemic acid (R) amide (S) R (-) Baclofen\n\nOn connaÃ®t Ã©galement, dans Canadian Journal of Chemistry, 1994, 72(1 1 ), 2312-2317, une voie de synthÃ¨se asymÃ©trique du R(-)BaclofÃ¨ne mettant en Åuvre une dÃ©symÃ©trisation d'un glutarate prochiral par la chymotrypsine selon le schÃ©ma suivant : Also known in the Canadian Journal of Chemistry, 1994, 72 (1 1), 2312-2317, is an asymmetric synthesis pathway for R (-) Baclofen, employing desymmetrization of a prochiral glutarate by chymotrypsin according to the following scheme :\n\nR(-)BaclofÃ¨ne Â R (-) Baclofen\n\nEnfin, la demande de brevet WO 94/02443 dÃ©crit une synthÃ¨se Ã©nantiosÃ©lective du R(-)BaclofÃ¨ne Ã partir d'un dÃ©rivÃ© de l'acide S-pyroglutamique selon le schÃ©ma suivant : Finally, the patent application WO 94/02443 describes an enantioselective synthesis of R (-) Baclofen from a derivative of S-pyroglutamic acid according to the following scheme:\n\nToutefois, ces mÃ©thodes mettent en Åuvre des rÃ©actifs coÃ»teux et difficilement industrialisables. De plus, le rendement final en R(-)BaclofÃ¨ne est assez faible. En outre, du fait du nombre d'Ã©tapes de synthÃ¨se, le produit final est contaminÃ© par des impuretÃ©s qui doivent Ãªtre Ã©liminÃ©es par des Ã©tapes de purification afin d'obtenir un produit suffisamment pur pour Ãªtre administrÃ© comme mÃ©dicament. However, these methods use expensive reagents and difficult to industrialize. In addition, the final yield of R (-) Baclofen is quite low. In addition, because of the number of synthesis steps, the final product is contaminated by impurities that must be removed by purification steps to obtain a sufficiently pure product to be administered as a drug.\n\nDans ce contexte, les inventeurs ont mis au point un procÃ©dÃ© permettant de sÃ©parer les Ã©nantiomÃ¨res du BaclofÃ¨ne en partant d'un mÃ©lange racÃ©mique. Ce procÃ©dÃ© est avantageusement industrialisable et ne requiert pas l'utilisation de dÃ©rivÃ©s chiraux. De plus, les Ã©tapes du procÃ©dÃ© de la prÃ©sente invention sont faciles Ã mettre en Åuvre et il n'y a aucune perte de matiÃ¨re premiÃ¨re grÃ¢ce aux recyclages successifs. Â In this context, the inventors have developed a method for separating the enantiomers of Baclofen starting from a racemic mixture. This process is advantageously industrializable and does not require the use of chiral derivatives. In addition, the process steps of the present invention are easy to implement and there is no loss of raw material through successive recycling.\n\nCe but est atteint grÃ¢ce Ã l'application du procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle au BaclofÃ¨ne racÃ©mique sous forme de sel. Ainsi, l'invention se rapporte tout particuliÃ¨rement Ã l'application Ã un sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne, du dÃ©doublement par cristallisation prÃ©fÃ©rentielle en chacun de ses Ã©nantiomÃ¨res, permettant d'obtenir l'eutomÃ¨re R(-)BaclofÃ¨ne dans une forme Ã©nantiomÃ©riquement et chimiquement pure. Â This goal is achieved by the application of the preferred crystallization process to racemic Baclofen in salt form. Thus, the invention relates particularly to the application to a racemic salt of Baclofen hydrogen maleate, the resolution by preferential crystallization in each of its enantiomers, to obtain the eutomer R (-) Baclofen in an enantiomerically and chemically pure.\n\nLe sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne peut Ãªtre rÃ©solu par n'importe quel type de cristallisation prÃ©fÃ©rentielle, notamment les plus avantageuses, c'est Ã dire les procÃ©dÃ©s auto-ensemencÃ©s. Â The racemic salt of Baclofen hydrogen maleate can be solved by any type of preferential crystallization, especially the most advantageous ones, ie the self-seeded processes.\n\nEn particulier, le procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle AS3PC a fait l'objet d'un dÃ©veloppement tout Ã fait original excluant l'utilisation contraignante de germes de cristallisation (i.e. sans ensemencement). Ce procÃ©dÃ© est dÃ©crit par exemple dans les brevets et demandes de brevet suivants : FR 2 710 337, WO 95/08522, EP 0 720 595 et US 6,022,409 et dans Â« G. Coquerel, Preferential Crystallization in Topic in Current Chemistry, Novel Optical Resolution Technologies, Springer, Berlin, Heidelberg, Eds. K. Sakai, N. Hirayama and R. Tamura Â», 2007, 269, 1-51. Ce procÃ©dÃ© est dÃ©signÃ© Â« AS3PC Â», pour \"Auto-Seeded Programmed Polythermic Preferential Crystallization\". Â In particular, the AS3PC preferential crystallization process has undergone a completely original development excluding the constraining use of crystallization seeds (i.e. without seeding). This process is described for example in the following patents and patent applications: FR 2,710,337, WO 95/08522, EP 0 720 595 and US 6,022,409 and in G. Coquerel, Novel Optical Resolution, Preferential Crystallization in Topic in Current Chemistry. Technologies, Springer, Berlin, Heidelberg, Eds. K. Sakai, N. Hirayama and R. Tamura, 2007, 269, 1-51. This process is referred to as \"AS3PC\" for \"Auto-Seeded Programmed Polythermic Preferential Crystallization\".\n\nUn autre procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle autoensemencÃ© est dÃ©crit dans la demande de brevet WO 201 1/07330. Ce procÃ©dÃ© est dÃ©signÃ© par l'acronyme: \"ASPreCISE\" pour \"Auto-Seeded PREferential Crystallization Induced by Solvent Evaporation\". Â Another preferred self-seeded crystallization process is described in patent application WO 201 1/07330. This process is designated by the acronym: \"ASPreCISE\" for \"Auto-Seeded PREFreential Crystallization Induced by Solvent Evaporation\".\n\nLes procÃ©dÃ©s de cristallisation prÃ©fÃ©rentielle reposent sur la cristallisation stÃ©rÃ©osÃ©lective alternÃ©e des deux Ã©nantiomÃ¨res (R) et (S), d'une mÃªme espÃ¨ce chimique racÃ©mique cristallisant sous forme de conglomÃ©rat, dans un mÃ©dium qui peut Ãªtre un solvant ou un mÃ©lange de solvants ou un ensemble de constituants incluant le ou les solvants, et ce pour une gamme donnÃ©e de tempÃ©rature ÎÎ¤. Dans cette gamme de tempÃ©rature, ce mÃ©lange racÃ©mique, en Ã©quilibre thermodynamique avec sa solution saturÃ©e, est constituÃ© de deux types de cristaux ne contenant chacun que des molÃ©cules de mÃªme configuration absolue. Â The preferential crystallization processes are based on the alternating stereoselective crystallization of the two enantiomers (R) and (S), of the same racemic chemical species crystallizing in the form of a conglomerate, in a medium which may be a solvent or a mixture of solvents or a solvent. set of constituents including the solvent (s) for a given temperature range ÎÎ¤. In this temperature range, this racemic mixture, in thermodynamic equilibrium with its saturated solution, consists of two types of crystals each containing only molecules of the same absolute configuration.\n\nLa connaissance de ces Ã©quilibres hÃ©tÃ©rogÃ¨nes Ã©nantiomÃ¨re (R) - Ã©nantiomÃ¨re (S) - solvant fournit des donnÃ©es mises Ã profit pour rÃ©aliser un dÃ©doublement efficace par cristallisation prÃ©fÃ©rentielle. Â The knowledge of these enantiomeric (R) - enantiomeric (S) - solvent heterogeneous equilibria provides data used to achieve effective resolution by preferential crystallization.\n\nLes Ã©tudes menÃ©es par la Demanderesse montrent que le BaclofÃ¨ne racÃ©mique ne cristallise pas sous forme d'un conglomÃ©rat. Cela signifie que l'on ne peut pas appliquer le procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle AS3PC ou ASPreCISE ou tout autre procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle. Dans l'optique de la mise en place d'un tel procÃ©dÃ©, une recherche d'un sel de BaclofÃ¨ne permettant la discrimination chirale a Ã©tÃ© effectuÃ©e par addition d'un co-formeur, tel qu'un acide, une base ou un mÃ©tal alcalin. La liste complÃ¨te des diffÃ©rents co-formeurs testÃ©s est prÃ©sentÃ©e dans le Tableau 1 ci-dessous : The studies conducted by the Applicant show that racemic Baclofen does not crystallize in the form of a conglomerate. This means that the preferred AS3PC or ASPreCISE crystallization process or any other preferred crystallization method can not be applied. In view of setting up such a method, a search for a salt of Baclofen allowing chiral discrimination has been carried out by adding a co-former, such as an acid, a base or a metal. alkaline. The complete list of the different co-formers tested is presented in Table 1 below:\n\nCo-formeurs : acides, bases ou mÃ©taux alcalins Co-formers: acids, bases or alkali metals\n\n(les composÃ©s en gras sont ceux pour lesquels une nouvelle phase est observÃ©e, la nouvelle phase Ã©tant un co-cristal comprenant le BaclofÃ¨ne et le co-formeur) Â (the compounds in bold are those for which a new phase is observed, the new phase being a co-crystal comprising Baclofen and the co-former)\n\nacide 4-nitrobenzoÃ¯que acide cholique acide adipique acide 3,4-dichlorobenzoÃ¯que acide 3-bromo-4-nitrobenzoÃ¯que acide 4-hydroxybenzÃ¨nesulfonique acide 4-fluoro- 3-nitrobenzoÃ¯que acide 3-fluoro-4-nitrobenzoÃ¯que acide dichloroacÃ©tique acide 2-chloro-4-nitrobenzoÃ¯que acide 2,5-dinitrobenzoÃ¯que acide tÃ©trafluoroborique acide 2,4-dihydroxybenzoÃ¯que acide 3-mÃ©thoxy-4-nitrobenzoÃ¯que acide trifluoromÃ©thanesulfonique acide 4-hydroxybenzoÃ¯que acide 2-chloro-3,5-dinitrobenzoÃ¯que acide acÃ©tique Â 4-nitrobenzoic acid cholic acid adipic acid 3,4-dichlorobenzoic acid 3-bromo-4-nitrobenzoic acid 4-hydroxybenzenesulfonic acid 4-fluoro-3-nitrobenzoic acid 3-fluoro-4-nitrobenzoic acid dichloroacetic acid 2-chloro-4 acid -nitrobenzoic acid 2,5-dinitrobenzoic acid tetrafluoroboric acid 2,4-dihydroxybenzoic acid 3-methoxy-4-nitrobenzoic acid trifluoromethanesulfonic acid 4-hydroxybenzoic acid 2-chloro-3,5-dinitrobenzoic acid acetic acid\n\nacide 2,4- acide 4-chloro-3,5-dinitrobenzoÃ¯que acide 2-mÃ©thyl-3,5-dinitrobenzoÃ¯que Â 2,4-Acidic acid 4-chloro-3,5-dinitrobenzoic acid 2-methyl-3,5-dinitrobenzoic acid\n\ndiaminobenzÃ¨nesulfonique acide 3,5-dinitro-4-toluique acide 3,5-dinitrosalicylique acide mÃ©thanesulfonique acide 4-mÃ©thyl-3-nitrobenzoÃ¯que acide 3-bromo-5-nitrobenzoÃ¯que acide 4-nitrobenzÃ¨nesulfonique acide 3-nitro-5- acide salicylique acide trichloroacÃ©tique (trifluoromÃ©thyl)benzoÃ¯que Â diaminobenzenesulfonic acid 3,5-dinitro-4-toluic acid 3,5-dinitrosalicylic acid methanesulfonic acid 4-methyl-3-nitrobenzoic acid 3-bromo-5-nitrobenzoic acid 4-nitrobenzenesulfonic acid 3-nitro-5-acid salicylic acid trichloroacetic acid (trifluoromethyl) benzoic acid\n\nacide 3,4-dinitrobenzoÃ¯que acide hydrocinnamique acide benzÃ¨nesulfonique Â 3,4-dinitrobenzoic acid hydrocinnamic acid benzenesulfonic acid\n\nacide 3,5-diamino-2,4,6- acide citraconique acide 5-chloro-2-nitrobenzoÃ¯que Â 3,5-diamino-2,4,6-acid citraconic acid 5-chloro-2-nitrobenzoic acid\n\ntrimÃ©thylbenzÃ¨nesulfonique acide 3,5-dinitrobenzoÃ¯que acide 2,5-dichlorobenzoÃ¯que acide 1 ,2-phÃ©nylÃ¨nediacÃ©tique Â trimethylbenzenesulfonic acid 3,5-dinitrobenzoic acid 2,5-dichlorobenzoic acid 1,2-phenylenediacetic acid\n\nacide 2,5- acide o-toluique acide fumarique Â 2.5-acid o-toluic acid fumaric acid\n\ndiaminobenzÃ¨nesulfonique acide 3-nitrobenzoÃ¯que acide 2-phÃ©nylbutyrique acide bromoacÃ©tique acide 4-chloro- 3-nitrobenzoÃ¯que acide 2-tÃ©trahydrofolique acide Ã©thanesulfonique acide trans-3,4- acide 3-mÃ©thyl-4-nitrobenzoÃ¯que acide mÃ©thanesulfonique dimÃ©thoxycinnamique Â diaminobenzenesulphonic acid 3-nitrobenzoic acid 2-phenylbutyric acid bromoacetic acid 4-chloro-3-nitrobenzoic acid 2-tetrahydrofolic acid ethanesulfonic acid trans-3,4-acid-acid 3-methyl-4-nitrobenzoic acid methanesulfonic acid dimethoxycinnamic\n\nacide oxalique acide 3-phÃ©nylbutyrique acide mÃ©thoxyacÃ©tique acide 4-chlorobenzÃ¨ne- acide mÃ©thylsulfamique hexamÃ©thylÃ¨netÃ©tramine Â oxalic acid 3-phenylbutyric acid methoxyacetic acid 4-chlorobenzene acid methylsulfamic acid hexamethylenetetramine\n\nsulfonique Â sulfonic\n\nacide butyl-Ã©thyl-hydroxy- acide stÃ©arique diphÃ©nylamine Â butyl-ethyl-hydroxy-stearic acid diphenylamine\n\npropionique Â propionic\n\nacide undÃ©canedioÃ¯que acide frans-cinnamique tÃ©t ra h y d rof u rf u ry la m i n e acide cis, c/s-muconique acide glutarique tert-butylamine Â acid undecanedioic acid frans-cinnamic tetrahydrofluoric acid cis, c / s-muconic acid glutaric tert-butylamine\n\nacide 2,4- acide isophtalique benzylamine diaminobenzenesulfonique Â 2,4-isophthalic acid benzylamine diaminobenzenesulfonic acid\n\nacide glycolique acide itaconique n-butylamine acide pimÃ©lique acide malonique Ã©thylÃ¨nediamine acide tÃ©tradÃ©canedioÃ¯que acide n-butyrique N,N'-dibenzylÃ©thylÃ¨nediamine acide mucique acide p-tolyacÃ©tique Ã©thanolamine acide subÃ©rique acide propionique ammoniaque Â glycolic acid itaconic acid n-butylamine pimelic acid malonic acid ethylenediamine tetradecanedioic acid n-butyric acid N, N'-dibenzylethylenediamine mucic acid p-tolyacetic acid ethanolamine suberic acid propionic acid ammonia\n\nacide 1 H-benzimidazol-2- acide sÃ©bacique triÃ©thanolamine Â 1H-benzimidazol-2-acid sebacic acid triethanolamine\n\nsulfonique Â sulfonic\n\nacide dodÃ©canadioÃ¯que acide 1-naphtalÃ¨ne-sulfonique hydroxyde de potassium acide urique acide 3-pyridinesulfonique hydroxyde de calcium acide succinique acide chloroacÃ©tique hydroxyde de magnÃ©sium acide borique acide 1-hydroxy-2-naphtoÃ¯que hydroxyde d'aluminium acide p-toluÃ¨nesulfonique dodecanadioic acid 1-naphthalenesulfonic acid potassium hydroxide uric acid 3-pyridinesulfonic acid calcium hydroxide succinic acid chloroacetic acid magnesium hydroxide boric acid 1-hydroxy-2-naphthoic acid aluminum hydroxide p-toluenesulfonic acid\n\nacide 1-propanesulfonique hydroxyde de strontium monohydratÃ© Â 1-Propanesulfonic Acid Strontium Hydroxide Monohydrate\n\nacide citrique acide iodoacÃ©tique hydroxyde de lithium monohydratÃ© acide nitrique acide chlorhydrique hydroxyde de sodium acide sulfurique acide bromique formiate de rubidium hydratÃ© acide phosphorique acide iodhydrique acide trifluoroacÃ©tique acide sulfamique acide perchlorique acide pyrophosphorique Â citric acid iodoacetic acid lithium hydroxide monohydrate nitric acid hydrochloric acid sodium hydroxide sulfuric acid bromic acid rubidium formate hydrated phosphoric acid phosphoric acid trifluoroacetic acid sulphamic acid perchloric acid pyrophosphoric acid\n\nTableau 1 Table 1\n\nPar contre, de maniÃ¨re tout Ã fait inattendue, la Demanderesse a trouvÃ©, que le BaclofÃ¨ne formait avec l'acide malÃ©ique un sel qui cristallise sans formation de solvate dans la plupart des solvants usuels et sans formation d'un eutectique en milieu fondu. Ce dÃ©rivÃ© salin prÃ©sente en outre l'avantage d'Ãªtre un sel pharmaceutiquement acceptable et peu onÃ©reux. De faÃ§on surprenante, ce sel prÃ©sente une discrimination chirale quasi-totale Ã tempÃ©rature ambiante mais aucune discrimination chirale Ã haute tempÃ©rature. Cette propriÃ©tÃ© a Ã©tÃ© utilisÃ©e pour dÃ©doubler le mÃ©lange racÃ©mique avec un rendement optimal par application rÃ©pÃ©tÃ©e de la cristallisation prÃ©fÃ©rentielle. De plus, le procÃ©dÃ© de dÃ©doublement peut Ãªtre mis en Åuvre dans l'eau en utilisant le dÃ©doublement auto-ensemencÃ© AS3PC pour une plus grande facilitÃ© d'exploitation Ã l'Ã©chelle industrielle By cons, quite unexpectedly, the Applicant has found that Baclofen formed with maleic acid a salt which crystallizes without solvate formation in most common solvents and without forming a eutectic in a molten medium. This salt derivative also has the advantage of being a pharmaceutically acceptable salt and inexpensive. Surprisingly, this salt has an almost total chiral discrimination at room temperature but no chiral discrimination at high temperature. This property was used to split the racemic mixture with optimal yield by repeated application of preferential crystallization. In addition, the splitting process can be implemented in water using self-seeded AS3PC splitting for greater ease of operation on an industrial scale.\n\nEXPOSÃ DE L'INVENTION STATEMENT OF THE INVENTION\n\nLa prÃ©sente invention a pour objet un sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne (Bahma) prÃ©sentant un point de fusion/dÃ©composition de 164Â±1 Â°C. Â The present invention relates to a racemic salt of Baclofen hydrogen maleate (Bahma) having a melting / decomposition point of 164 Â± 1 Â° C.\n\nUn autre objet de l'invention est l'utilisation du sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne pour dÃ©doubler les Ã©nantiomÃ¨res (S) et (R) du BaclofÃ¨ne. Â Another object of the invention is the use of the racemic salt of Baclofen hydrogen maleate to split the enantiomers (S) and (R) of Baclofen.\n\nLa prÃ©sente invention a Ã©galement pour objet un procÃ©dÃ© de dÃ©doublement des Ã©nantiomÃ¨res (S) et (R) du BaclofÃ¨ne, dans lequel le BaclofÃ¨ne racÃ©mique est transformÃ© en sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne en prÃ©sence d'acide malÃ©ique et dans lequel ledit sel est dÃ©doublÃ© par cristallisation prÃ©fÃ©rentielle pour sÃ©parer les deux Ã©nantiomÃ¨res (S) et (R). Â The present invention also relates to a process for resolving the (S) and (R) enantiomers of Baclofen, in which the racemic Baclofen is converted into the racemic salt of Baclofen hydrogen maleate in the presence of maleic acid and in which said salt is resolved by preferential crystallization to separate the two enantiomers (S) and (R).\n\nLa prÃ©sente invention a Ã©galement pour objet un procÃ©dÃ© de purification Ã©nantiomÃ©rique de sels d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne comprenant la recristallisation de sels d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne dans un solvant. Â The present invention also relates to a process for the enantiomeric purification of Baclofen hydrogen maleate salts comprising the recrystallization of hydrogen maleate salts of Baclofen in a solvent.\n\nLa prÃ©sente invention a Ã©galement pour objet un sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne de configuration absolue R(-) ou un sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne tel qu'obtenu par les procÃ©dÃ©s de la prÃ©sente invention, pour son utilisation dans le traitement de la sclÃ©rose en plaques, de paralysies ou de la dÃ©pendance alcoolique. Â The subject of the present invention is also a Baconofen hydrogen maleate salt of R (-) absolute configuration or a Baclofen hydrogen maleate salt as obtained by the methods of the present invention for its use in the treatment of sclerosis. in patches, paralysis or alcohol dependence.\n\nDESCRIPTION DÃTAILLÃE DETAILED DESCRIPTION\n\nLe sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne objet de la prÃ©sente invention prÃ©sente un point de fusion/dÃ©composition de 164Â±1 Â°C. Le point de fusion/dÃ©composition est mesurÃ© par calorimÃ©trie diffÃ©rentielle Ã balayage (DSC) selon la mÃ©thode dÃ©crite ci-aprÃ¨s. Le terme Â« Bahma Â» utilisÃ© dans la prÃ©sente demande dÃ©signe Â« hydrogÃ©nomalÃ©ate de BaclofÃ¨ne Â». The racemic salt of Baclofen hydrogen maleate which is the subject of the present invention has a melting / decomposition point of 164 Â± 1 Â° C. The melting / decomposition point is measured by differential scanning calorimetry (DSC) according to the method described below. The term \"Bahma\" as used herein refers to \"Baclofen hydrogen maleate\".\n\nLe point de fusion/dÃ©composition correspond au point de fusion du sel Bahma qui est suivi ou s'accompagne d'une dÃ©composition du sel Bahma. En effet, le sel Bahma peut subir une ou plusieurs rÃ©actions de dÃ©composition, par exemple la formation de l'anhydride malÃ©ique ou l'estÃ©rification du baclofÃ¨ne ou une autre rÃ©action de dÃ©composition. Â The melting / decomposition point corresponds to the melting point of the Bahma salt which is followed or is accompanied by a decomposition of the Bahma salt. Indeed, the Bahma salt can undergo one or more decomposition reactions, for example the formation of maleic anhydride or the esterification of baclofen or other decomposition reaction.\n\nLedit sel rÃ©pond Ã la formule Ainsi, la fonction aminÃ© du BaclofÃ¨ne est protonÃ©e et il y a une seule molÃ©cule de BaclofÃ¨ne et une seule molÃ©cule d'hydrogÃ©nomalÃ©ate dans l'unitÃ© asymÃ©trique. La masse molaire du sel est 329.73 g. mol\"1. Said salt meets the formula Thus, the amino function of Baclofen is protonated and there is a single molecule of Baclofen and a single molecule of hydrogen maleate in the asymmetric unit. The molar mass of salt is 329.73 g. mol \"1 .\n\nLedit sel peut notamment Ãªtre obtenu en dissolvant un mÃ©lange racÃ©mique de BaclofÃ¨ne et d'acide malÃ©ique dans des proportions stÅchiomÃ©triques dans un solvant ou mÃ©lange de solvants. Â Said salt can in particular be obtained by dissolving a racemic mixture of Baclofen and maleic acid in stoichiometric proportions in a solvent or mixture of solvents.\n\nLa rÃ©action de salification peut notamment Ãªtre mise en Åuvre dans un solvant choisi parmi l'acÃ©tone, l'eau, le mÃ©thanol, l'azÃ©otrope eau/n-propanol et leurs mÃ©langes. Â The salification reaction can in particular be carried out in a solvent selected from acetone, water, methanol, azeotrope water / n-propanol and mixtures thereof.\n\nAfin d'assurer une bonne cristallisation, il est avantageux de dissoudre le BaclofÃ¨ne et l'acide malÃ©ique dans un volume de solvant le plus faible possible. De plus, pour atteindre une solution homogÃ¨ne, le mÃ©lange peut Ãªtre chauffÃ©. Â In order to ensure good crystallization, it is advantageous to dissolve Baclofen and maleic acid in the smallest possible solvent volume. In addition, to achieve a homogeneous solution, the mixture can be heated.\n\nAprÃ¨s dissolution des solides, on laisse la solution revenir Ã tempÃ©rature ambiante et les cristaux se forment par Ã©vaporation du solvant en quelques jours. Â After dissolution of the solids, the solution is allowed to return to room temperature and the crystals are formed by evaporation of the solvent in a few days.\n\nLes monocristaux obtenus prÃ©sentent un faciÃ¨s caractÃ©ristique avec des zones de rÃ©flexion totale, le long de l'axe de plus grand dÃ©veloppement du cristal, tel que prÃ©sentÃ© Ã laÂ The monocrystals obtained have a characteristic facies with zones of total reflection, along the axis of greatest development of the crystal, as presented in FIG.\n\nFigure 1. Figure 1.\n\nLes sels (R) et (S) d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne de la prÃ©sente invention prÃ©sentent une solution solide totale Ã haute tempÃ©rature, notamment Ã une tempÃ©rature supÃ©rieure Ã 150Â°C. En effet, le diagramme de phase des deux Ã©nantiomÃ¨res de la Figure 2 montre qu'il existe un domaine monophasÃ© unique, c'est-Ã -dire une solution solide totale, au-delÃ de 150Â°C. En dessous de cette tempÃ©rature, qui correspond exactement au point critique maximum de la dÃ©mixtion Ã l'Ã©tat solide du mÃ©lange racÃ©mique, il y une discrimination chirale Ã l'Ã©tat solide qui s'amplifie Ã mesure que la tempÃ©rature est abaissÃ©e. Â The (R) and (S) salts of Baclofen hydrogen maleate of the present invention exhibit a total solid solution at high temperature, especially at a temperature above 150 Â° C. Indeed, the phase diagram of the two enantiomers of Figure 2 shows that there is a single single-phase domain, that is to say a total solid solution, above 150 Â° C. Below this temperature, which corresponds exactly to the maximum critical point of the solid phase demixing of the racemic mixture, there is solid chiral discrimination which increases as the temperature is lowered.\n\nDe faÃ§on inattendue, la Figure 2 montre Ã©galement qu'il existe une discrimination chirale quasi-totale Ã une tempÃ©rature infÃ©rieure ou Ã©gale Ã 70Â°C. Ainsi, en dessous de 70Â°C, le domaine monophasÃ© est trÃ¨s faible en composition, c'est-Ã -dire moins de <1 % de l'autre Ã©nantiomÃ¨re, de chaque cÃ´tÃ© du diagramme de phase binaire. Cette large lacune de dÃ©mixtion offre une discrimination chirale Ã l'Ã©tat solide trÃ¨s importante qui peut Ãªtre mise Ã profit pour mettre en Åuvre un dÃ©doublement par cristallisation prÃ©fÃ©rentielle ou une purification Ã©nantiomÃ©rique prÃ©parative i.e. sans perte d'excÃ¨s Ã©nantiomÃ©rique. Â Unexpectedly, Figure 2 also shows that there is near total chiral discrimination at a temperature of less than or equal to 70 Â° C. Thus, below 70 Â° C, the single-phase domain is very low in composition, i.e. less than <1% of the other enantiomer, on either side of the binary phase diagram. This broad demixing gap provides a very important solid state chiral discrimination that can be used to implement preferential crystallization splitting or preparative enantiomeric purification i.e. without loss of enantiomeric excess.\n\nCe comportement Ã©tait d'autant moins anticipÃ© que le BaclofÃ¨ne et l'acide malÃ©ique offrent de multiples possibilitÃ©s de liaisons hydrogÃ¨nes dirigÃ©es peu propices Ã la formation de solution solide. Ce cas trÃ¨s rare de solution solide totale avec dÃ©mixtion Ã l'Ã©tat solide se diffÃ©rencie des cas plus classiques de conglomÃ©rats avec solution solide partielle dont le diagramme de phase est reprÃ©sentÃ© Ã la Figure 3. This behavior was all the less anticipated that Baclofen and maleic acid offer multiple possibilities of directed hydrogen bonds not conducive to the formation of solid solution. This very rare case of total solid solution with solid state demixing differs from the case more classical conglomerates with partial solid solution whose phase diagram is shown in Figure 3.\n\nIl est Ã noter que de nombreux sels de BaclofÃ¨ne autres que Bahma ont Ã©tÃ© Ã©tudiÃ©s (cf. Tableau 1 ci-dessus). Toutefois, leurs diagrammes de phase binaires, semblables Ã celui reprÃ©sentÃ© Ã la Figure 4, ne prÃ©sentent pas de solution solide totale ni de discrimination chirale ce qui ne permet pas d'envisager un dÃ©doublement par cristallisation prÃ©fÃ©rentielle. Â It should be noted that many Baclofen salts other than Bahma have been studied (see Table 1 above). However, their binary phase diagrams, similar to that shown in Figure 4, do not present a total solid solution or chiral discrimination which does not allow to consider preferential resolution crystallization.\n\nAinsi, de par son comportement spÃ©cifique, l'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne est, a priori, tout Ã fait appropriÃ© Ã une utilisation pour dÃ©doubler les Ã©nantiomÃ¨res (S) et (R) du BaclofÃ¨ne. Thus, because of its specific behavior, Baclofen hydrogen maleate is, a priori, quite suitable for use in resolving the (S) and (R) enantiomers of Baclofen.\n\nL'invention a Ã©galement pour objet un procÃ©dÃ© de dÃ©doublement des Ã©nantiomÃ¨res (S) et (R) du BaclofÃ¨ne, dans lequel on transforme le BaclofÃ¨ne racÃ©mique en sel racÃ©mique d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne en prÃ©sence d'acide malÃ©ique. Le sel racÃ©mique de Bahma obtenu est ensuite dÃ©doublÃ© par cristallisation prÃ©fÃ©rentielle pour sÃ©parer les deux Ã©nantiomÃ¨res (S) et (R). The subject of the invention is also a process for resolving the (S) and (R) enantiomers of Baclofen, in which racemic Baclofen is converted into the racemic salt of Baclofen hydrogen maleate in the presence of maleic acid. The racemic salt of Bahma obtained is then resolved by preferential crystallization to separate the two enantiomers (S) and (R).\n\nLe dÃ©doublement du sel racÃ©mique de Bahma peut notamment Ãªtre rÃ©alisÃ© par cristallisation prÃ©fÃ©rentielle autoensemencÃ©e (AS3PC ou ASPreCISE) ou par cristallisation prÃ©fÃ©rentielle ensemencÃ©e, de prÃ©fÃ©rence par cristallisation prÃ©fÃ©rentielle autoensemencÃ©e. Â The resolution of the racemic salt of Bahma can in particular be carried out by preferential self-seeded crystallization (AS3PC or ASPreCISE) or by preferential crystallization seeded, preferably by preferential self-seeded crystallization.\n\nSelon un mode de rÃ©alisation particulier du procÃ©dÃ© de la prÃ©sente invention, la cristallisation prÃ©fÃ©rentielle est mise en Åuvre avec un solvant choisi parmi un solvant alcoolique, une solution aqueuse, une solution aqueuse acide et les mÃ©langes de ceux-ci. Â According to a particular embodiment of the process of the present invention, the preferential crystallization is carried out with a solvent selected from an alcoholic solvent, an aqueous solution, an acidic aqueous solution and mixtures thereof.\n\nDes exemples de solvants alcooliques pouvant Ãªtre utilisÃ©s sont le mÃ©thanol, l'Ã©thanol, le n-propanol et leurs mÃ©langes, en particulier le n-propanol. Â Examples of alcoholic solvents which can be used are methanol, ethanol, n-propanol and mixtures thereof, in particular n-propanol.\n\nSelon un mode de rÃ©alisation particulier, le solvant est un mÃ©lange azÃ©otropique de n- propanol et d'eau. Â According to a particular embodiment, the solvent is an azeotropic mixture of n-propanol and water.\n\nSelon un mode de rÃ©alisation prÃ©fÃ©rÃ©, la cristallisation prÃ©fÃ©rentielle est mise en Åuvre avec une solution aqueuse acide, l'acide Ã©tant choisi parmi l'acide chlorhydrique, l'acide acÃ©tique, l'acide nitrique, de prÃ©fÃ©rence une solution aqueuse d'acide chlorhydrique, plus prÃ©fÃ©rentiellement une solution aqueuse d'acide chlorhydrique Ã 2 mol/L. Â According to a preferred embodiment, the preferential crystallization is carried out with an acidic aqueous solution, the acid being chosen from hydrochloric acid, acetic acid and nitric acid, preferably an aqueous solution of hydrochloric acid. more preferably an aqueous solution of hydrochloric acid at 2 mol / l.\n\nEn effet, la solubilitÃ© de Bahma dans une solution aqueuse acidifiÃ©e est supÃ©rieure Ã celle de Bahma dans de l'eau ou dans un mÃ©lange azÃ©otropique de n-propanol et d'eau. Cette meilleure solubilitÃ© permet d'augmenter la productivitÃ© de la cristallisation prÃ©fÃ©rentielle. Â In fact, the solubility of Bahma in an acidified aqueous solution is greater than that of Bahma in water or in an azeotropic mixture of n-propanol and water. This better solubility makes it possible to increase the productivity of the preferential crystallization.\n\nSelon un mode de rÃ©alisation particulier, la cristallisation prÃ©fÃ©rentielle est autoensemencÃ©e et comprend les Ã©tapes suivantes : Â According to a particular embodiment, the preferential crystallization is self-seeded and comprises the following steps:\n\na) on prÃ©pare un volume V d'une solution saturÃ©e de sel racÃ©mique de Bahma dans un solvant Ã une tempÃ©rature TL ; a) preparing a volume V of a saturated solution of racemic salt of Bahma in a solvent at a temperature T L ;\n\nb) on ajoute au moins 5% en poids du premier Ã©nantiomÃ¨re Bahma Ã rÃ©cupÃ©rer par rapport au poids du sel racÃ©mique de Bahma ; Â b) adding at least 5% by weight of the first Bahma enantiomer to be recovered based on the weight of the racemic Bahma salt;\n\nc) on chauffe le mÃ©lange Ã une tempÃ©rature TB = TL + ÎÎ¤; c) the mixture is heated to a temperature T B = T L + ÎÎ¤;\n\nd) on applique une loi de programmation de refroidissement au mÃ©lange de TB Ã TF, TF Ã©tant infÃ©rieur Ã TB, telle que le mÃ©lange garde une faible sursaturation qui privilÃ©gie la croissance du premier Ã©nantiomÃ¨re Bahma prÃ©sent sous forme de cristaux, tout en interdisant la nuclÃ©ation spontanÃ©e du second Ã©nantiomÃ¨re Bahma dissous dans la solution ; d) applying a cooling programming law to the mixture of T B to T F , T F being less than T B , such that the mixture keeps a low supersaturation which favors growth the first Bahma enantiomer present in the form of crystals, while prohibiting the spontaneous nucleation of the second Bahma enantiomer dissolved in the solution;\n\ne) on rÃ©colte les cristaux du premier Ã©nantiomÃ¨re Bahma Ã la tempÃ©rature TF ; e) the crystals of the first Bahma enantiomer are harvested at the temperature T F ;\n\nf) on ajoute au mÃ©lange sensiblement la mÃªme masse de sel racÃ©mique de Bahma que la masse de la rÃ©colte rÃ©alisÃ©e Ã l'Ã©tape prÃ©cÃ©dente, on complÃ¨te avec du solvant pour atteindre le volume V et on porte le nouvel ensemble Ã la tempÃ©rature TB ; f) adding to the mixture substantially the same mass of racemic Bahma salt as the mass of the crop made in the previous step, complete with solvent to reach the volume V and bring the new set to the temperature T B ;\n\ng) on maintient la tempÃ©rature TB pendant un temps t afin de permettre au systÃ¨me de revenir Ã l'Ã©quilibre thermodynamique ; g) maintaining the temperature T B for a time t to allow the system to return to thermodynamic equilibrium;\n\nh) on applique la mÃªme loi de programmation de refroidissement qu'Ã l'Ã©tape (d) au mÃ©lange prÃ©parÃ© Ã l'Ã©tape (g) contenant le second Ã©nantiomÃ¨re Bahma, de sorte que le mÃ©lange garde une faible sursaturation pendant la cristallisation afin de privilÃ©gier la croissance du second Ã©nantiomÃ¨re Bahma prÃ©sent sous forme de cristaux tout en interdisant la nuclÃ©ation spontanÃ©e du premier Ã©nantiomÃ¨re Bahma prÃ©sent dans la solution ; Â h) applying the same cooling programming law as in step (d) to the mixture prepared in step (g) containing the second Bahma enantiomer, so that the mixture keeps a slight supersaturation during crystallization in order to favoring the growth of the second Bahma enantiomer present in the form of crystals while preventing the spontaneous nucleation of the first Bahma enantiomer present in the solution;\n\nj) on rÃ©colte les cristaux du second Ã©nantiomÃ¨re Bahma Ã la tempÃ©rature TF ; j) the crystals of the second Bahma enantiomer are harvested at the temperature T F ;\n\nj) on ajoute au mÃ©lange sensiblement la mÃªme masse de sel racÃ©mique de Bahma que la masse de la rÃ©colte rÃ©alisÃ©e Ã l'Ã©tape prÃ©cÃ©dente, on complÃ¨te avec du solvant pour atteindre le volume V et on porte le nouvel ensemble Ã la tempÃ©rature TB ; j) the same mass of racemic Bahma salt is added to the mixture as the mass of the crop made in the previous step, the mixture is made up with solvent to reach the volume V and the new assembly is brought to the temperature T B ;\n\nk) on maintient la tempÃ©rature TB pendant un temps t afin de permettre au systÃ¨me de revenir Ã l'Ã©quilibre thermodynamique ; k) maintaining the temperature T B for a time t to allow the system to return to thermodynamic equilibrium;\n\nI) on rÃ©pÃ¨te les Ã©tapes (d) Ã (k) pour obtenir successivement l'un puis l'autre des deux Ã©nantiomÃ¨res. Â I) steps (d) to (k) are repeated to successively obtain one then the other of the two enantiomers.\n\nDans le procÃ©dÃ© ci-dessus, le solvant est tel que dÃ©crit prÃ©cÃ©demment, notamment un mÃ©lange azÃ©otropique de n-propanol et d'eau ou une solution aqueuse acide. Le volume V de solvant utilisÃ© pour obtenir une solution saturÃ©e est dÃ©terminÃ© en fonction de la quantitÃ© de sel racÃ©mique de Bahma Ã dÃ©doubler et de la solubilitÃ© du sel racÃ©mique de Bahma dans le solvant choisi. Â In the above process, the solvent is as previously described, especially an azeotropic mixture of n-propanol and water or an aqueous acidic solution. The volume V of solvent used to obtain a saturated solution is determined as a function of the amount of racemic Bahma salt to be resolved and the solubility of the racemic Bahma salt in the selected solvent.\n\nÃ l'Ã©tape (b) du procÃ©dÃ© ci-dessus, la quantitÃ© du premier Ã©nantiomÃ¨re Bahma ajoutÃ©e est d'au moins 5% en poids par rapport au poids du sel racÃ©mique de Bahma dissous dans le solvant, en particulier de 5 Ã 15% en poids, plus particuliÃ¨rement de 5 Ã 10% en poids. Â In step (b) of the above process, the amount of the first added Bahma enantiomer is at least 5% by weight based on the weight of the racemic Bahma salt dissolved in the solvent, in particular 5 to 15% by weight. by weight, more particularly from 5 to 10% by weight.\n\nÃ l'Ã©tape (c) du procÃ©dÃ© ci-dessus, la tempÃ©rature TL correspond Ã la tempÃ©rature de dissolution du mÃ©lange racÃ©mique seul dans le solvant selon l'Ã©tape (a). Selon un mode de rÃ©alisation particulier, la tempÃ©rature TL va de 30 Ã 70Â°C, de prÃ©fÃ©rence TL va de 40 Ã 60Â°C, plus prÃ©fÃ©rentiellement TL est 50Â°C. In step (c) of the above process, the temperature T L corresponds to the dissolution temperature of the racemic mixture alone in the solvent according to step (a). According to a particular embodiment, the temperature T L is from 30 to 70 Â° C, preferably T L is from 40 to 60 Â° C, more preferably T L is 50 Â° C.\n\nÃ l'Ã©tape (c) du procÃ©dÃ© ci-dessus la tempÃ©rature TB correspond Ã une tempÃ©rature lÃ©gÃ¨rement supÃ©rieure Ã la tempÃ©rature de dissolution du mÃ©lange racÃ©mique TL. Ainsi, la tempÃ©rature TB = TL + ÎÎ¤ oÃ¹ ÎÎ¤ va de 1 Â°C Ã 10Â°C, en particulier de 2Â°C Ã 7Â°C, plus particuliÃ¨rement de 3Â°C Ã 5Â°C. In step (c) of the above process the temperature T B corresponds to a temperature slightly higher than the dissolution temperature of the racemic mixture T L. Thus, the temperature T B = T L + ÎÎ¤ where ÎÎ¤ ranges from 1 Â° C to 10 Â° C, in particular from 2 Â° C to 7 Â° C, more particularly from 3 Â° C to 5 Â° C.\n\nAvantageusement, dans les Ã©tapes (d) et (h) du procÃ©dÃ© ci-dessus, on adapte pendant toute la durÃ©e de la croissance cristalline une vitesse d'agitation lÃ©gÃ¨rement croissante en fonction du temps de faÃ§on Ã ce que celle-ci soit suffisamment lente pour favoriser une croissance du premier ou du second Ã©nantiomÃ¨re Bahma, en Ã©vitant de gÃ©nÃ©rer une nuclÃ©ation non maÃ®trisÃ©e et l'attrition de cristaux. Advantageously, in the steps (d) and (h) of the above process, a slightly increasing stirring speed as a function of time is adjusted throughout the duration of the crystalline growth so that it is sufficiently slow to foster growth of first or second Bahma enantiomer, avoiding generating uncontrolled nucleation and attrition of crystals.\n\nDans le procÃ©dÃ© ci-dessus, la tempÃ©rature TF dÃ©pend de la quantitÃ© de sel racÃ©mique de Bahma que l'on souhaite dÃ©doubler. Selon un mode de rÃ©alisation particulier, la tempÃ©rature TF va de 20 Ã 40Â°C, de prÃ©fÃ©rence TF va de 25 Ã 35Â°C, plus prÃ©fÃ©rentiellement TF est 30Â°C. In the above process, the temperature T F depends on the amount of racemic salt of Bahma that one wishes to split. According to a particular embodiment, the temperature T F is 20 to 40 Â° C, preferably T F is 25 to 35 Â° C, more preferably T F is 30 Â° C.\n\nDans le procÃ©dÃ© ci-dessus, le temps t dÃ©pend de la quantitÃ© de sel racÃ©mique de Bahma que l'on souhaite dÃ©doubler. Selon un mode de rÃ©alisation particulier, le temps t est supÃ©rieur Ã 20 min, de prÃ©fÃ©rence de 25 min Ã 45 min, plus prÃ©fÃ©rentiellement t est 30 min. Â In the above process, the time t depends on the amount of racemic salt of Bahma that one wishes to split. According to a particular embodiment, the time t is greater than 20 min, preferably 25 min to 45 min, more preferably t is 30 min.\n\nAux Ã©tapes (e) et (i) du procÃ©dÃ© ci-dessus, les cristaux du premier Ã©nantiomÃ¨re Bahma et les cristaux du second Ã©nantiomÃ¨re Bahma sont rÃ©coltÃ©s par filtration ou centrifugation. Â In steps (e) and (i) of the above process, the crystals of the first Bahma enantiomer and the crystals of the second Bahma enantiomer are harvested by filtration or centrifugation.\n\nLes cristaux du premier Ã©nantiomÃ¨re Bahma et les cristaux du second Ã©nantiomÃ¨re Bahma obtenus avec le procÃ©dÃ© objet de la prÃ©sente invention peuvent notamment prÃ©senter un excÃ¨s Ã©nantiomÃ©rique supÃ©rieur Ã 80%. Lesdits cristaux peuvent Ãªtre recristallisÃ©s pour obtenir un excÃ¨s Ã©nantiomÃ©riques proche de 100%, notamment selon le procÃ©dÃ© de purification Ã©nantiomÃ©rique selon l'invention dÃ©crit ci-aprÃ¨s. Un solvant appropriÃ© pour la recristallisation est un solvant choisi parmi l'acÃ©tone, l'eau, le mÃ©thanol, l'azÃ©otrope eau/n-propanol et leurs mÃ©langes. Â The crystals of the first Bahma enantiomer and the crystals of the second Bahma enantiomer obtained with the process that is the subject of the present invention may in particular have an enantiomeric excess greater than 80%. Said crystals may be recrystallized to obtain an enantiomeric excess close to 100%, in particular according to the enantiomeric purification method according to the invention described hereinafter. A suitable solvent for recrystallization is a solvent selected from acetone, water, methanol, azeotrope water / n-propanol and mixtures thereof.\n\nSelon un deuxiÃ¨me mode de rÃ©alisation, la cristallisation prÃ©fÃ©rentielle est ensemencÃ©e et comprend les Ã©tapes suivantes : According to a second embodiment, the preferential crystallization is seeded and comprises the following steps:\n\na) on prÃ©pare une premiÃ¨re solution homogÃ¨ne composÃ©e du sel racÃ©mique de Bahma, d'un excÃ¨s du premier Ã©nantiomÃ¨re de Bahma Ã rÃ©cupÃ©rer et d'un solvant, dont le point figuratif I, dÃ©fini par les variables concentration et tempÃ©rature \"Î (T| > THOMO), se situe dans le domaine monophasÃ© composÃ© de la solution sous-saturÃ©e ; a) preparing a first homogeneous solution composed of the racemic salt of Bahma, an excess of the first Bahma enantiomer to be recovered and a solvent, the figurative point I of which is defined by the concentration and temperature variables \" Î (T | > T H OMO), is in the single-phase domain composed of the undersaturated solution;\n\nb) on applique une loi de programmation de refroidissement au mÃ©lange monophasÃ© ; c) lorsque le mÃ©lange atteint une tempÃ©rature infÃ©rieure Ã la tempÃ©ratu re THOMO> on ensemence la solution avec des germes Ã©nantiomÃ©riquement purs du premier Ã©nantiomÃ¨re Bahma Ã rÃ©cupÃ©rer ; b) applying a cooling programming law to the single-phase mixture; c) when the mixture reaches a temperature below the temperatu re thomo> the solution is seeded with enantiomerically pure seeds of the first enantiomer Bahma to be recovered;\n\nd) on adapte pendant toute la durÃ©e de la croissance cristalline une vitesse d'agitation lÃ©gÃ¨rement croissante en fonction du temps de faÃ§on Ã ce que celle-ci soit suffisamment lente pour favoriser une croissance du premier Ã©nantiomÃ¨re Bahma ; Â d) during the entire duration of the crystalline growth, a slightly increasing stirring rate is adjusted as a function of time so that the latter is slow enough to promote growth of the first Bahma enantiomer;\n\ne) on rÃ©colte les cristaux du premier Ã©nantiomÃ¨re Bahma ; Â e) the crystals of the first Bahma enantiomer are collected;\n\nf) on ajoute au mÃ©lange la mÃªme masse de sel racÃ©mique de Bahma que la masse de la rÃ©colte rÃ©alisÃ©e Ã l'Ã©tape prÃ©cÃ©dente, et on porte le nouvel ensemble Ã la tempÃ©rature \"Î (T| > THOMO), le point Î se situant dans le domaine monophasÃ© ; f) the same racemic salt of Bahma is added to the mixture as the mass of the crop made in the previous step, and the new set is brought to the temperature \" Î (T |> THOMO) , the point Î being in the single-phase domain;\n\ng) on applique la mÃªme loi de programmation de refroidissement qu'Ã l'Ã©tape (b) au mÃ©lange monophasÃ© prÃ©parÃ© Ã l'Ã©tape (f) contenant le second Ã©nantiomÃ¨re, de sorte que le mÃ©lange garde une faible sursaturation pendant la cristallisation afin de privilÃ©gier la croissance du second Ã©nantiomÃ¨re Bahma lors de l'ensemencement; Â g) the same cooling programming law is applied as in step (b) to the single-phase mixture prepared in step (f) containing the second enantiomer, so that the mixture keeps a low supersaturation during crystallization in order to favor the growth of the second Bahma enantiomer during seeding;\n\nh) lorsque le mÃ©lange atteint une tempÃ©rature infÃ©rieure Ã la tempÃ©ratu re THOMO> on ensemence la solution avec des germes Ã©nantiomÃ©riquement purs du second Ã©nantiomÃ¨re Bahma ; i) on adapte pendant toute la durÃ©e de la croissance cristalline de l'Ã©tape prÃ©cÃ©dente, une vitesse d'agitation lÃ©gÃ¨rement croissante en fonction du temps de faÃ§on Ã ce que celle-ci soit, suffisamment lente pour favoriser la croissance de ce second Ã©nantiomÃ¨re Bahma ; h) when the mixture reaches a temperature below the temperatu re thomo> the solution is seeded with enantiomerically pure seeds of the second enantiomer Bahma; i) during the entire duration of the crystalline growth of the preceding step, a slightly increasing rate of stirring as a function of time is adjusted so that the latter is slow enough to promote the growth of this second Bahma enantiomer; ;\n\nj) on rÃ©colte les cristaux du second Ã©nantiomÃ¨re Bahma ; Â j) the crystals of the second Bahma enantiomer are collected;\n\nk) on ajoute au mÃ©lange la mÃªme masse de sel racÃ©mique de Bahma que la masse de la rÃ©colte rÃ©alisÃ©e Ã l'Ã©tape prÃ©cÃ©dente, pour obtenir une solution dont la composition est identique Ã celle de la solution initiale ; Â k) adding to the mixture the same mass of racemic Bahma salt as the mass of the crop made in the previous step, to obtain a solution whose composition is identical to that of the initial solution;\n\nI) on rÃ©pÃ¨te les Ã©tapes (b) Ã (k) pour obtenir successivement l'un puis l'autre des deux Ã©nantiomÃ¨res. La prÃ©sente invention a Ã©galement pour objet un procÃ©dÃ© de purification Ã©nantiomÃ©rique de sels de Bahma comprenant la recristallisation de sels de Bahma dans un solvant. Le solvant peut notamment Ãªtre choisi parmi acÃ©tone, eau, mÃ©thanol, azÃ©otrope eau/n-propanol et leurs mÃ©langes. Â I) steps (b) to (k) are repeated to successively obtain one then the other of the two enantiomers. The present invention also relates to a process for the enantiomeric purification of Bahma salts comprising the recrystallization of Bahma salts in a solvent. The solvent may especially be chosen from acetone, water, methanol, water / n-propanol azeotrope and mixtures thereof.\n\nLe procÃ©dÃ© de purification Ã©nantiomÃ©rique de la prÃ©sente invention peut notamment Ãªtre mis en Åuvre Ã la suite du procÃ©dÃ© de dÃ©doublement des Ã©nantiomÃ¨res du BaclofÃ¨ne selon la prÃ©sente invention dÃ©crit ci-dessus. Â The enantiomeric purification method of the present invention may in particular be implemented following the resolution process of the enantiomers of Baclofen according to the present invention described above.\n\nLe procÃ©dÃ© de purification Ã©nantiomÃ©rique de la prÃ©sente invention repose sur l'exploitation du diagramme de phase ternaire comprenant le domaine des solutions solides et les solubilitÃ©s du systÃ¨me {Solvant - EnantiomÃ¨re (R) de Bahma - EnantiomÃ¨re (S) de Bahma}, reprÃ©sentÃ© Ã la Figure 7. Â The enantiomeric purification method of the present invention is based on the exploitation of the ternary phase diagram comprising the domain of solid solutions and the solubilities of the Bahma Bahma-Enantiomer (S) (Bahma) Enantiomeric (R) system, shown in FIG. Figure 7.\n\nCette figure reprÃ©sente une coupe isotherme et isobare du diagramme de phase ternaire entre les sels des 2 Ã©nantiomÃ¨res de Bahma et un solvant, la tempÃ©rature choisie permettant la forte discrimination chirale entre les 2 Ã©nantiomÃ¨res. En partant d'un mÃ©lange de sels d'Ã©nantiomÃ¨res (R) et (S) de Bahma de composition I connue, qui peut notamment Ãªtre un mÃ©lange d'Ã©nantiomÃ¨res (R) et (S) obtenu lors du procÃ©dÃ© de cristallisation prÃ©fÃ©rentielle selon la prÃ©sente invention, et en ajoutant du solvant, on traverse diffÃ©rents domaines constituÃ©s de phases ayant chacune une composition et une nature diffÃ©rente : Â This figure represents an isothermal and isobaric section of the ternary phase diagram between the salts of the two enantiomers of Bahma and a solvent, the chosen temperature allowing the strong chiral discrimination between the two enantiomers. Starting from a mixture of enantiomeric salts (R) and (S) of Bahma of known composition I, which can in particular be a mixture of enantiomers (R) and (S) obtained during the preferred crystallization process according to the present invention, and by adding solvent, crosses different domains consisting of phases each having a composition and a different nature:\n\nI H0 : domaine triphasÃ© constituÃ© des 2 Ã©nantiomÃ¨res de Bahma sous forme solide (ssR et ssS) et de la solution racÃ©mique saturÃ©e (s.s.r.) ; IH 0 : three-phase domain consisting of 2 enantiomers of Bahma in solid form (ssR and ssS) and saturated racemic solution (ssr);\n\nH0 -> G : domaine biphasÃ© constituÃ© d'un sel enrichi en l'Ã©nantiomÃ¨re (R) de Bahma (ssR) sous forme solide et de sa solution saturÃ©e (sol.sat.), la proportion en cristaux d'Ã©nantiomÃ¨re (R) de Bahma diminuant tout au long du segment [H0G], le point H0 Ã©tant le point le plus riche en cristaux d'Ã©nantiomÃ¨re (R) de Bahma ; H 0 -> G: two-phase domain consisting of a salt enriched in the enantiomer (R) of Bahma (ssR) in solid form and its saturated solution (sol.sat.), The proportion of enantiomeric crystals (R ) of Bahma decreasing throughout the segment [H 0 G], the point H 0 being the richest point in Bahma enantiomer crystals (R);\n\nG -> F : domaine monophasÃ© constituÃ© d'une solution sous-saturÃ©e (U.S. S). Â G -> F: single-phase domain consisting of an undersaturated solution (U.S. S).\n\nAinsi, en connaissant prÃ©cisÃ©ment la composition initiale du mÃ©lange I et sa masse, les domaines de solutions solides et la solubilitÃ© du mÃ©lange racÃ©mique, on peut dÃ©terminer avec prÃ©cision la composition du point H0, qui permet, par filtration, de sÃ©parer le sel enrichi en l'Ã©nantiomÃ¨re (R) de Bahma sous forme solide, reprÃ©sentÃ© par le point P0, de la solution racÃ©mique l_o saturÃ©e. Ce point H0 Ã©tant atteint par ajout d'un volume VHo de solvant ou une masse mHo de solvant au mÃ©lange I. On peut Ã©galement ajouter un volume de solvant VHi lÃ©gÃ¨rement supÃ©rieur Ã VHo (Vm = VHo + Î\\/) ou une masse de solvant mHi lÃ©gÃ¨rement supÃ©rieure Ã mHo (mm = ÎÎ ÎÎ + Îm) afin d'atteindre le point de composition Hi . AprÃ¨s filtration on sÃ©pare le sel enrichi en l'Ã©nantiomÃ¨re (R) de Bahma sous forme solide, reprÃ©sentÃ© par le point Pi , de la solution racÃ©mique l_i saturÃ©e. L'ajout de cette quantitÃ© de solvant VHi ou mHi permet l'obtention d'un sel comprenant une plus forte proportion d'Ã©nantiomÃ¨re (R) de Bahma que celui obtenu en ajoutant une quantitÃ© de solvant VHo ou ITIHO- En revanche, le rendement en sel enrichi en ajoutant une quantitÃ© de solvant VHi ou mHi est plus faible que celui obtenu en ajoutant une quantitÃ© de solvant VHo ou mHo puisqu'une quantitÃ© plus importante d'Ã©nantiomÃ¨re (R) de Bahma reste dissous dans la solution saturÃ©e. Plus la quantitÃ© de solvant AV ou ÎÎ¹ÏÎ¹ est faible et plus la quantitÃ© d'Ã©nantiomÃ¨re (R) de Bahma qui reste dissous dans la solution saturÃ©e est limitÃ©e. Thus, by knowing precisely the initial composition of the mixture I and its mass, the solid solution domains and the solubility of the racemic mixture, it is possible to accurately determine the composition of the H 0 point, which allows, by filtration, to separate the enriched salt. to the Bahma enantiomer (R) in solid form, represented by the point P 0 , of saturated racemic solution 1 o. This point H 0 being reached by adding a volume V H o of solvent or a mass m H o of solvent to the mixture I. It is also possible to add a solvent volume V H i that is slightly greater than V H o (V m = V H o + Î \\ /) or a mass of solvent m H i slightly greater than m H o (mm = ÎÎ ÎÎ + Îm). in order to reach the composition point Hi. After filtration, the enriched salt is separated into the Bahma enantiomer (R) in solid form, represented by the Pi point, of the saturated racemic solution. The addition of this amount of solvent V H i or m H i makes it possible to obtain a salt comprising a higher proportion of Bahma enantiomer (R) than that obtained by adding a quantity of solvent V H o or ITIHO - On the other hand, the salt yield enriched by adding a quantity of solvent V H i or m H i is lower than that obtained by adding a quantity of solvent V H o or m H o since a larger amount of enantiomer (R) Bahma remains dissolved in the saturated solution. The lower the amount of AV or ÎÎ¹ÏÎ¹ solvent, the smaller the amount of Bahma enantiomer (R) remaining dissolved in the saturated solution.\n\nLa Figure 7 illustre le procÃ©dÃ© de purification Ã©nantiomÃ©rique pour un mÃ©lange initialement enrichi en Ã©nantiomÃ¨re (R) de Bahma, mais le procÃ©dÃ© peut Ãªtre appliquÃ© symÃ©triquement Ã un mÃ©lange enrichi en Ã©nantiomÃ¨re (S) de Bahma. Â Figure 7 illustrates the enantiomeric purification method for a mixture initially enriched with Bahma enantiomer (R), but the process can be applied symmetrically to a mixture enriched with Bahma (S) enantiomer.\n\nAinsi, selon un mode de rÃ©alisation prÃ©fÃ©rÃ©, le procÃ©dÃ© de purification Ã©nantiomÃ©rique de sel de Bahma selon la prÃ©sente invention comprend les Ã©tapes suivantes : Â Thus, according to a preferred embodiment, the enantiomeric purification method of Bahma salt according to the present invention comprises the following steps:\n\na) fournir un mÃ©lange solide d'Ã©nantiomÃ¨res (R) et (S) de Bahma de composition connue reprÃ©sentÃ© par le point I sur la coupe isotherme et isobare du diagramme de phase ternaire entre les 2 Ã©nantiomÃ¨res de Bahma et un solvant ; Â a) providing a solid mixture of Bahma (R) and (S) enantiomers of known composition represented by point I on the isothermal and isobaric section of the ternary phase diagram between the two Bahma enantiomers and a solvent;\n\nb) ajouter une quantitÃ© de solvant de faÃ§on Ã passer dans le domaine biphasÃ© constituÃ© d'un sel enrichi en un Ã©nantiomÃ¨re de Bahma sous forme solide et de sa solution saturÃ©e dudit diagramme de phase ternaire ; Â b) adding a quantity of solvent to pass into the two-phase domain consisting of a salt enriched in a Bahma enantiomer in solid form and its saturated solution of said ternary phase diagram;\n\nc) filtrer le mÃ©lange obtenu Ã l'Ã©tape b) pour obtenir le sel enrichi en un Ã©nantiomÃ¨re deÂ c) filtering the mixture obtained in step b) to obtain the salt enriched in one enantiomer of\n\nBahma. Bahma.\n\nDe prÃ©fÃ©rence, la quantitÃ© de solvant ajoutÃ©e dans l'Ã©tape b) est le volume VHo ou la masse mHo de solvant qui permet d'atteindre le point H0 sur ledit diagramme de phase, ledit point H0 correspondant Ã l'intersection de la droite passant entre le point I et le point F, le point F Ã©tant le sommet du diagramme de phase correspondant au solvant pur, et de la droite P0-L0 (i.e. la conode) dÃ©limitant le domaine triphasÃ© du domaine biphasÃ© du sel enrichi en Ã©nantiomÃ¨re de Bahma que l'on souhaite obtenir. Preferably, the quantity of solvent added in step b) is the volume V H o or the mass m H o of solvent that makes it possible to reach the point H 0 on said phase diagram, said point H 0 corresponding to the intersection of the line passing between the point I and the point F, the point F being the apex of the phase diagram corresponding to the pure solvent, and of the line P 0 -L 0 (ie the conode) delimiting the three-phase domain of the domain two-phase salt enriched enantiomeric Bahma that is desired.\n\nDe prÃ©fÃ©rence, la quantitÃ© de solvant ajoutÃ©e dans l'Ã©tape b) est le volume VHi = VHo + AV ou la masse mHi = mHo + ÎÎ¹ÏÎ¹ de solvant qui permet d'atteindre le point t sur ledit diagramme de phase, ledit point t correspondant Ã l'intersection de la droite passant entre le point I et le point F, le point F Ã©tant le sommet du diagramme de phase correspondant au solvant pur, et de la droite P-r l_i (i.e. la conode). Preferably, the amount of solvent added in step b) is the volume V H i = V H o + AV or the mass m H i = m H o + ÎÎ¹ÏÎ¹ of solvent which makes it possible to reach the point t on said phase diagram, said point t corresponding to the intersection of the straight line passing between the point I and the point F, the point F being the top of the phase diagram corresponding to the pure solvent, and of the straight line Pr l_i (ie the conode ).\n\nLes sels de Bahma obtenus avec le procÃ©dÃ© de dÃ©doublement de la prÃ©sente invention et/ou le procÃ©dÃ© de purification Ã©nantiomÃ©rique de la prÃ©sente invention peuvent Ãªtre transformÃ©s en BaclofÃ¨ne ou en un sel de BaclofÃ¨ne autre que le sel de Bahma sans racÃ©misation, c'est-Ã -dire sans perte d'excÃ¨s Ã©nantiomÃ©rique. La transformation de sels de Bahma en BaclofÃ¨ne peut notamment Ãªtre rÃ©alisÃ©e par ajout d'une base. La prÃ©sente invention a Ã©galement pour objet un sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne de configuration absolue R(-) ou un sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne tel qu'obtenu par les procÃ©dÃ©s de la prÃ©sente invention, pour son utilisation dans le traitement de la sclÃ©rose en plaques, de paralysies ou de la dÃ©pendance alcoolique. En effet, le sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne est pharmaceutiquement acceptable. De plus, le procÃ©dÃ© de la prÃ©sente invention ne gÃ©nÃ¨re aucun sous-produit Ã Ã©liminer ce qui permet d'utiliser le sel d'hydrogÃ©nomalÃ©ate de BaclofÃ¨ne directement obtenu par le procÃ©dÃ© dÃ©crit ci-dessus dans le traitement de la sclÃ©rose en plaques, de paralysies ou de la dÃ©pendance alcoolique. The Bahma salts obtained with the resolution method of the present invention and / or the enantiomeric purification method of the present invention can be converted to Baclofen or a Baclofen salt other than Bahma salt without racemization, that is, that is, without loss of enantiomeric excess. The transformation of Bahma salts into Baclofen can in particular be carried out by adding a base. The subject of the present invention is also a Baconofen hydrogen maleate salt of R (-) absolute configuration or a Baclofen hydrogen maleate salt as obtained by the methods of the present invention for its use in the treatment of sclerosis. in patches, paralysis or alcohol dependence. Indeed, the hydrogen maleate salt of Baclofen is pharmaceutically acceptable. In addition, the process of the present invention does not generate any by-product to be eliminated, which makes it possible to use the Baclofen hydrogen maleate salt directly obtained by the process described above in the treatment of multiple sclerosis, paralysis or alcohol dependence.\n\nL'invention sera maintenant illustrÃ©e par les exemples non limitatifs suivants. FIGURES The invention will now be illustrated by the following nonlimiting examples. FIGURES\n\nLa Figure 1 est un clichÃ© de microscopie optique d'un monocristal ayant un excÃ¨s Ã©nantiomÃ©rique de 98.6% issu d'un sel racÃ©mique de Bahma prÃ©parÃ© Ã l'exemple 1. Â Figure 1 is an optical micrograph of a monocrystal having an enantiomeric excess of 98.6% from a racemic salt of Bahma prepared in Example 1.\n\nLa Figure 2 est le diagramme de phase binaire de Bahma obtenu par calorimÃ©trie diffÃ©rentielle Ã balayage (DSC) (la courbe liquidus n'est pas prÃ©sente Ã©tant donnÃ© que le sel Bahma se dÃ©compose pendant ou aprÃ¨s sa fusion). Â Figure 2 is the differential scanning calorimetry (DSC) binary phase diagram of Bahma (the liquidus curve is not present since the Bahma salt decomposes during or after its melting).\n\nLa Figure 3 est un diagramme de phase binaire thÃ©orique d'un conglomÃ©rat prÃ©sentant une solution solide partielle. Â Figure 3 is a theoretical binary phase diagram of a conglomerate having a partial solid solution.\n\nLa Figure 4 est un diagramme de phase binaire thÃ©orique d'un sel de BaclofÃ¨ne autre que le sel de Bahma avec la prÃ©sence usuelle d'un composÃ© racÃ©mique stÅchiomÃ©trique. Â Figure 4 is a theoretical binary phase diagram of a Baclofen salt other than Bahma salt with the usual presence of a stoichiometric racemic compound.\n\nLa Figure 5 reprÃ©sente la droite d'Ã©talonnage tracÃ©e en faisant varier la concentration (C) d'un Ã©nantiomÃ¨re pur de Bahma et en mesurant le pouvoir rotatoire spÃ©cifique (a) Ã une longueur d'onde de 365 nm dans l'azÃ©otrope eau/n-propanol Ã 25Â°C. Â Figure 5 shows the calibration line plotted by varying the concentration (C) of a pure Bahma enantiomer and measuring the specific rotational power (a) at a wavelength of 365 nm in the water / water azeotrope. n-propanol at 25 Â° C.\n\nLa Figure 6 reprÃ©sente le diffractogramme DRX calculÃ© et mesurÃ© du sel racÃ©mique de Bahma de l'exemple 1. Â Figure 6 shows the calculated and measured DRX diffractogram of the racemic Bahma salt of Example 1.\n\nLa Figure 7 reprÃ©sente l'isotherme isobare ternaire du systÃ¨me {EnantiomÃ¨re (R) deÂ Figure 7 represents the ternary isobar isotherm of the system (Enantiomer (R) of\n\nBahma - EnantiomÃ¨re (S) de Bahma - Solvant} illustrant le procÃ©dÃ© de purification Ã©nantiomÃ©rique de la prÃ©sente invention. Bahma - Bahma - Solvent (S) enantiomer} illustrating the enantiomeric purification method of the present invention.\n\nLa Figure 8 est une comparaison des diffractogrammes, obtenus par analyse de diffraction des rayons X, de la forme B du (R)(-) BaclofÃ¨ne et du Test 1 de l'exemple 5. Â Figure 8 is a comparison of diffractograms, obtained by X-ray diffraction analysis, of form B of (R) (-) Baclofen and Test 1 of Example 5.\n\nLa Figure 9 correspond au spectre RMN H du Test 1 de l'exemple 5 dans le DMSO deutÃ©rÃ©. Â Figure 9 corresponds to the 1 H NMR spectrum of Test 1 of Example 5 in deuterated DMSO.\n\nLa Figure 10 est une comparaison des diffractogrammes, obtenus par analyse de diffraction des rayons X, de la forme B du (R)(-) BaclofÃ¨ne et du Test 2 de l'exemple 5. Â Figure 10 is a comparison of diffractograms, obtained by X-ray diffraction analysis, of form B of (R) (-) Baclofen and Test 2 of Example 5.\n\nLa Figure 11 correspond au spectre RMN H du Test 2 de l'exemple 5 dans le DMSO deutÃ©rÃ©. Â Figure 11 corresponds to the 1 H NMR spectrum of Test 2 of Example 5 in deuterated DMSO.\n\nLa Figure 12 est une comparaison des diffractogrammes, obtenus par analyse de diffraction des rayons X, de la forme B du (R)(-) BaclofÃ¨ne et du Test 3 de l'exemple 5. Â Figure 12 is a comparison of diffractograms, obtained by X-ray diffraction analysis, of form B of (R) (-) Baclofen and Test 3 of Example 5.\n\nLa Figure 13 correspond au spectre RMN H du Test 3 de l'exemple 5 dans le DMSO deutÃ©rÃ©. La Figure 14 correspond au spectre RMN H du sel d'hydrogÃ©nomalÃ©ate de baclofÃ¨ne dans l'eau deutÃ©rÃ©e. Figure 13 corresponds to the 1 H NMR spectrum of Test 3 of Example 5 in deuterated DMSO. Figure 14 corresponds to the H NMR spectrum of the baclofen hydrogen maleate salt in deuterated water.\n\nLa Figure 15 correspond au spectre RMN H du baclofÃ¨ne dans l'eau deutÃ©rÃ©e. Â Figure 15 corresponds to the H NMR spectrum of baclofen in deuterated water.\n\nLa Figure 16 correspond au spectre RMN H de l'acide MalÃ©ique dans l'eau deutÃ©rÃ©e. Â Figure 16 corresponds to the 1 H NMR spectrum of maleic acid in deuterated water.\n\nTECHNIQUES ANALYTIQUES ANALYTICAL TECHNIQUES\n\nDÃ©termination du point de fusion/dÃ©composition et obtention du diagramme de phase binaire par calorimÃ©trie diffÃ©rentielle Ã balayage (DSC) Determination of the melting / decomposition point and obtaining the binary phase diagram by differential scanning calorimetry (DSC)\n\nLes mesures calorimÃ©triques diffÃ©rentielles Ã balayage ont Ã©tÃ© rÃ©alisÃ©es de la faÃ§on suivante : Â Differential scanning calorimetry measurements were performed as follows:\n\nâ¢ DSC 204 F1 Netzsch Ã©quipÃ© d'un Intracooler Â â¢ DSC 204 F1 Netzsch equipped with an Intracooler\n\nâ¢ Creuset Aluminium, couvercle Aluminium fermÃ© Â â¢ Aluminum crucible, aluminum lid closed\n\nâ¢ AtmosphÃ¨re: HÃ©lium Â â¢ Atmosphere: Helium\n\nâ¢ Vitesse de chauffe: 5K. min\"1 â¢ Heating rate: 5K. min \"1\n\nÂ· Traitement des donnÃ©es: logiciel Netzsch Proteus Thermal Analysis (v.4. 8. 4) Â· Data processing: Netzsch Proteus Thermal Analysis software (v.4.8.4)\n\nSuite aux diffÃ©rentes analyses DSC et HPLC chirale rÃ©alisÃ©es sur des monocristaux obtenus Ã 20 et 70Â°C (98.3%ee Ã 70Â°C et 98.8%ee Ã 20Â°C), le diagramme de phase binaire de la Figure 1 a Ã©tÃ© Ã©tabli. L'excÃ¨s Ã©nantiomÃ©rique (%ee) a Ã©tÃ© dÃ©terminÃ© par HPLC chirale selon la mÃ©thode dÃ©crite ci-dessous. Â Following various DSC and chiral HPLC analyzes performed on single crystals obtained at 20 and 70 Â° C (98.3% ee at 70 Â° C and 98.8% ee at 20 Â° C), the binary phase diagram of Figure 1 was established. The enantiomeric excess (% ee) was determined by chiral HPLC according to the method described below.\n\nDÃ©termination de l'excÃ¨s Ã©nantiomÃ©rigue (%ee) par HPLC chirale Determination of enantiomeric excess (% ee) by chiral HPLC\n\nLa mÃ©thode chromatographique provient de celle dÃ©crite dans Hefnawy, M . , Aboul-Enein, H. Talanta, 2003, vol. 61 , nÂ°5, pp. 667-673. Â The chromatographic method comes from that described in Hefnawy, M. , Aboul-Enein, H. Talanta, 2003, vol. 61, No. 5, pp. 667-673.\n\nLes excÃ¨s Ã©nantiomÃ©riques ont Ã©tÃ© dÃ©terminÃ©s par chromatographie HPLC chirale Ã l'aide d'une colonne Chirobiotic T (longueur 15 cm, diamÃ¨tre interne 4,6 mm, particules 5 Î¼Î¹ÏÎ¹) montÃ©e sur une chaÃ®ne HPLC Spectra System munie d'un passeur d'Ã©chantillon AS, d'une pompe P1000 et d'un dÃ©tecteur UV1000. Les conditions expÃ©rimentales Ã©taient : Â The enantiomeric excesses were determined by chiral HPLC chromatography using a Chirobiotic T column (length 15 cm, internal diameter 4.6 mm, particles 5 Î¼Î¹ÏÎ¹) mounted on a HPLC Spectra System chain equipped with a ferrymer. AS sample, P1000 pump and UV1000 detector. The experimental conditions were:\n\n- Solvant : mÃ©lange isocratique de mÃ©thanol, d'eau , d'acide acÃ©tique et de triÃ©thylamine en proportion 98 : 2 : 0.1 : 0.1 ; Â Solvent: isocratic mixture of methanol, water, acetic acid and triethylamine in a proportion of 98: 2: 0.1: 0.1;\n\n- DÃ©bit : 1 ml. min\"1 ; - Flow: 1 ml. min \"1 ;\n\n- DÃ©tecteur : Î» = 226 nm ; Â - Detector: Î» = 226 nm;\n\n- Volume injectÃ© : 10 [iL Â - Volume injected: 10 [iL\n\nDÃ©termination de l'excÃ¨s Ã©nantiomÃ©rigue (%ee) par polarimÃ©trie Determination of enantiomeric excess (% ee) by polarimetry\n\nEntre chaque cristallisation prÃ©fÃ©rentielle, les excÃ¨s Ã©nantiomÃ©rique (%ee) des prÃ©cipitÃ©s et de la solution ont Ã©galement Ã©tÃ© dÃ©terminÃ©s par polarimÃ©trie. Cette technique est plus rapide que l'analyse HPLC chirale et permet donc de vÃ©rifier le bon dÃ©roulement du procÃ©dÃ© de dÃ©doublement afin d'ajuster les paramÃ¨tres en consÃ©quence (quantitÃ© de solvant et de sel racÃ©mique de Bahma Ã compenser avant le dÃ©but d'une cristallisation). Ces analyses ont Ã©tÃ© effectuÃ©es sur un polarimÃ¨tre Perkin Elmer Model 341 muni d'une cellule de mesure de 10 cm thermostatÃ©e et permettant l'analyse Ã diffÃ©rentes longueurs d'onde. Les mesures ont Ã©tÃ© faites Ã 25Â°C et les Ã©chantillons ont Ã©tÃ© dissous dans l'azÃ©otrope eau/n- propanol (43.29 %mol). Le tableau ci-dessous donne le pouvoir rotatoire spÃ©cifique (a) d'un Ã©nantiomÃ¨re pur de Bahma Ã diffÃ©rentes longueurs d'ondes (Î»). Between each preferential crystallization, the enantiomeric excesses (% ee) of the precipitates and the solution were also determined by polarimetry. This technique is faster than chiral HPLC analysis and thus allows to verify the smooth running of the resolution process in order to adjust the parameters accordingly (amount of racemic salt and salt of Bahma to compensate before the start of a crystallization ). These analyzes were performed on a Perkin Elmer Model 341 polarimeter equipped with a 10 cm thermostatic measuring cell and allowing analysis at different wavelengths. The measurements were made at 25 Â° C. and the samples were dissolved in the water / n-propanol azeotrope (43.29 mol%). The table below gives the specific rotational power (a) of a pure Bahma enantiomer at different wavelengths (Î»).\n\nLa longueur d'onde de 365 nm a Ã©tÃ© retenue car elle prÃ©sentait la meilleure dÃ©viation de la lumiÃ¨re polarisÃ©e (-0.35Â°). Â The wavelength of 365 nm was chosen because it had the best deflection of the polarized light (-0.35 Â°).\n\nLa Figure 5 montre la droite d'Ã©talonnage qui a Ã©tÃ© tracÃ©e en faisant varier la concentration de l'Ã©nantiomÃ¨re pur de Bahma et en mesurant le pouvoir rotatoire spÃ©cifique Ã une longueur d'onde de 365 nm. Les valeurs sont reportÃ©es dans le tableau ci-aprÃ¨s. Figure 5 shows the calibration line that has been plotted by varying the concentration of the pure Bahma enantiomer and measuring the specific rotational power at a wavelength of 365 nm. The values are shown in the table below.\n\nOn a alors pu dÃ©duire la valeur du pouvoir rotatoire spÃ©cifique de Bahma avec la formule suivante: dans laquelle : Â It was then possible to deduce the value of the specific rotary power of Bahma with the following formula: in which:\n\na est le pouvoir rotatoire de l'Ã©chantillon en degrÃ©s (Â°) ; a is the rotational power of the sample in degrees (Â°);\n\nC est la concentration de l'Ã©chantillon en g.dL\" ; C is the concentration of the sample in g.dL \" ;\n\nI est la longueur de la cellule d'analyse en dm ; I is the length of the analysis cell in dm;\n\n[a] 365nm es* 'e pouvoir rotatoire spÃ©cifique de Bahma Ã 25Â°C et Ã 365 nm dans le solvant utilisÃ© exprimÃ© en Â°.dL.g\" .dm\"1. [A] 365nm * es e specific rotation of Bahma at 25 Â° C and at 365 nm in the solvent used in Â° .dL.g \".dm\" 1.\n\nLe pouvoir rotatoire spÃ©cifique de Bahma dans ces conditions est de 0.1642 Â°dL.g\" .dm\"1. Analyse par diffraction des rayons X sur monocristal The specific rotatory power of Bahma under these conditions is 0.1642 Â° dLg \" .dm \" 1 . Single crystal X-ray diffraction analysis\n\nLe monocristal choisi a Ã©tÃ© collÃ© au bout d'une baguette de verre et montÃ© sur une tÃªte goniomÃ©trique du diffractomÃ¨tre Bruker SMART APEX muni d'un dÃ©tecteur bidimensionnel. Trois ensembles de mesures ont Ã©tÃ© enregistrÃ©s (au total 1800 clichÃ©s (frames)) correspondant Ã 3 Ï balayages (scans) (incrÃ©mentation de 0.3Â°), pour quatre valeurs diffÃ©rentes de Ï. Â The selected single crystal was glued to the end of a glass rod and mounted on a goniometric head of the Bruker SMART APEX diffractometer equipped with a two-dimensional detector. Three sets of measurements were recorded (in total 1800 frames) corresponding to 3 Ï scans (incrementation of 0.3 Â°), for four different values of Ï.\n\nLes paramÃ¨tres de la maille Ã©lÃ©mentaire et la matrice d'orientation ont Ã©tÃ© dÃ©terminÃ©s en utilisant le programme SMART. Les intÃ©grations des donnÃ©es et raffinement des paramÃ¨tres de maille ont Ã©tÃ© rÃ©alisÃ©s Ã l'aide du programme SAINT. Les intensitÃ©s ont Ã©tÃ© corrigÃ©es du facteur de polarisation de Lorentz et d'absorption par les programmes SAINT et SADABS pour obtenir les F0 2.(hkl). Le programme WinGX a Ã©tÃ© utilisÃ© pour la dÃ©termination du groupe d'espace, la rÃ©solution de la structure et son affinement. The parameters of the elementary mesh and the orientation matrix were determined using the SMART program. The data integrations and refinement of the mesh parameters were carried out using the SAINT program. The intensities were corrected for the Lorentz polarization factor and for absorption by the SAINT and SADABS programs to obtain the F 0 2 (hkl). The WinGX program was used for the determination of the space group, the resolution of the structure and its refinement.\n\nAnalyse par diffraction des rayons X sur poudres Â X-ray diffraction analysis on powders\n\nLes analyses de diffraction des rayons X sur poudres ont Ã©tÃ© rÃ©alisÃ©es avec un diffractomÃ¨tre D8 Discover (Bruker). L'instrument est Ã©quipÃ© d'un tube Ã rayons X contenant une anticathode de cuivre (40kV, 40 mA, radiation Ka1 = 1.5406 A, radiation Ka2 = 1.5444 A) et est montÃ© avec un dÃ©tecteur angulaire Lynx eye. Le programme d'analyse utilisÃ© est un balayage 3 Ã 30Â° en 2Î par pas de 0.04Â° avec 0.5s/pas et une rotation de 20rpm (Phi spinner). Â X-ray powder diffraction analyzes were performed with a D8 Discover diffractometer (Bruker). The instrument is equipped with an X-ray tube containing a copper anticathode (40kV, 40mA, Ka1 radiation = 1.5406A, Ka2 radiation = 1.5444A) and is mounted with a Lynx eye angular detector. The analysis program used is a 30 Â° sweep at 2 Â° in steps of 0.04 Â° with 0.5s / step and a rotation of 20rpm (Phi spinner).\n\nDÃ©termination de solubilitÃ© Determination of solubility\n\nLa solubilitÃ© d'un sel de Bahma dans un solvant donnÃ© a Ã©tÃ© calculÃ©e, pour une tempÃ©rature donnÃ©e et dans un volume de solvant donnÃ©, avec la formule suivante: The solubility of a Bahma salt in a given solvent was calculated, for a given temperature and in a given solvent volume, with the following formula:\n\ndans laquelle in which\n\nmBahma es* 'a masse du sel de Bahma introduite en grammes pour atteindre la saturation ; mbahma is a mass of Bahma salt introduced in grams to reach saturation;\n\nPsoivant est la densitÃ© du solvant en g.mL\" ; etThe solvent is the density of the solvent in gmL \" and\n\nsoivant est le volume du solvant en mL. Dispositif expÃ©rimental pour le dÃ©doublement par cristallisation prÃ©fÃ©rentielle The solvent is the volume of the solvent in ml. Experimental device for resolution by preferential crystallization\n\nLes cristallisations ont Ã©tÃ© effectuÃ©es dans des tubes fermÃ©s (diamÃ¨tre 3cm, longueur 9cm). L'agitation Ã©tait assurÃ©e par des barreaux aimantÃ©s en forme de croix et le contrÃ´le en tempÃ©rature par un cryothermostat programmable Lauda ECO RE 415. Â The crystallizations were carried out in closed tubes (diameter 3 cm, length 9 cm). The stirring was ensured by magnetic cross bars and temperature control by a Lauda ECO RE 415 programmable cryothermostat.\n\nLes entraÃ®nements ont Ã©tÃ© mis en Åuvre par le procÃ©dÃ© AS3PC dÃ©crit dans la demande de brevet WO 1995/008522. Â The drives were implemented by the AS3PC process described in patent application WO 1995/008522.\n\nAu cours des entraÃ®nements, des Ã©chantillons des solutions (10 [iL diluÃ© dans 1 mL de phase mobile) ont Ã©tÃ© prÃ©levÃ©s afin de dÃ©terminer leurs excÃ¨s Ã©nantiomÃ©rique par chromatographie selon la mÃ©thode dÃ©crite ci-dessus. Â During the workouts, samples of the solutions (10 Î¼L diluted in 1 mL of mobile phase) were taken to determine their enantiomeric excess by chromatography according to the method described above.\n\na) PremiÃ¨re cristallisation Â a) First crystallization\n\nOn a prÃ©parÃ© un volume V de 40mL de solution de sel racÃ©mique de Bahma saturÃ©e Ã Â A volume V of 40mL of racemic salt solution of racially saturated Bahma was prepared.\n\n50Â°C (tempÃ©rature TL) dans un solvant ou un mÃ©lange de solvant par filtration d'une suspension Ã cette mÃªme tempÃ©rature aprÃ¨s un temps d'Ã©quilibration de plusieurs heures pour atteindre la saturation. 50 Â° C (temperature T L ) in a solvent or solvent mixture by filtration of a suspension at this same temperature after an equilibration time of several hours to reach saturation.\n\nA cette solution limpide sont ajoutÃ©s au moins 5% en poids d'excÃ¨s d'un Ã©nantiomÃ¨re pur de Bahma (Bahma-100%ee) par rapport au poids du sel de Bahma racÃ©mique (Bahma rac.) introduit. La suspension obtenue est ensuite lÃ©gÃ¨rement surchauffÃ©e Ã une tempÃ©rature TB = TL +3Â°C. Ainsi, tous les germes de l'Ã©nantiomÃ¨re en dÃ©faut pouvant subsister Ã TL sont nÃ©cessairement dissous. Le systÃ¨me de dÃ©part est donc une suspension de l'Ã©nantiomÃ¨re en excÃ¨s. La phase liquide de la suspension est saturÃ©e en un Ã©nantiomÃ¨re et lÃ©gÃ¨rement sous-saturÃ©e en l'autre Ã©nantiomÃ¨re. Ce systÃ¨me prÃ©sente l'avantage d'Ãªtre Ã l'Ã©quilibre thermodynamique. To this clear solution is added at least 5% by weight of excess of a pure enantiomer of Bahma (Bahma-100% ee) relative to the weight of the racemic Bahma salt (Bahma rac.) Introduced. The suspension obtained is then slightly superheated at a temperature T B = T L + 3 Â° C. Thus, all the seeds of the enantiomer in default that can remain at T L are necessarily dissolved. The starting system is therefore a suspension of the enantiomer in excess. The liquid phase of the suspension is saturated with one enantiomer and slightly under-saturated with the other enantiomer. This system has the advantage of being at thermodynamic equilibrium.\n\nUne rampe de tempÃ©rature de refroidissement est ensuite appliquÃ©e au systÃ¨me de TB Ã A cooling temperature ramp is then applied to the T B system at\n\nTF (TF < TB), tempÃ©rature finale Ã laquelle le systÃ¨me est rapidement filtrÃ© sans attendre l'Ã©tablissement de l'Ã©quilibre thermodynamique. T F (T F <T B ), the final temperature at which the system is rapidly filtered without waiting for the establishment of thermodynamic equilibrium.\n\nb) Cristallisations suivantes Â b) Crystallizations following\n\nA la fin de chaque entraÃ®nement, les suspensions ont Ã©tÃ© filtrÃ©es sur verre frittÃ©. Un Ã©chantillon des filtrats (10 [iL de filtrat diluÃ© dans 1 mL de phase mobile) a Ã©tÃ© rÃ©cupÃ©rÃ© pour analyse du %ee par HPLC chirale et le restant a Ã©tÃ© mis de cÃ´tÃ© pour rÃ©aliser l'entraÃ®nement suivant. Le solide rÃ©cupÃ©rÃ© a Ã©tÃ© pesÃ© puis 15 mg ont Ã©tÃ© dissous dans 1 .5 mL d'azÃ©otrope eau/n-propanol pour analyse du %ee par polarimÃ©trie et 10 [iL de cette solution ont Ã©tÃ© diluÃ©s dans 1 mL de phase mobile pour analyse du %ee par HPLC chirale. Â At the end of each training, the suspensions were filtered on sintered glass. A sample of the filtrates (10 .mu.l of filtrate diluted in 1mL of mobile phase) was recovered for analysis of% ee by chiral HPLC and the remainder was set aside to conduct the next workout. The recovered solid was weighed and then 15 mg was dissolved in 1.5 mL of water / n-propanol azeotrope for polarimetry analysis of the% ee and 10 Î¼L of this solution was diluted in 1 mL of mobile phase for analysis. % ee by chiral HPLC.\n\nLe filtrat rÃ©cupÃ©rÃ© a Ã©tÃ© compensÃ© en ajoutant une masse de sel racÃ©mique de Bahma sensiblement Ã©gale Ã celle des cristaux rÃ©cupÃ©rÃ©s Ã la cristallisation prÃ©cÃ©dente. Le filtrat a aussi Ã©tÃ© compensÃ© des pertes en solvant en ajoutant du solvant jusqu'Ã atteindre 40 mL (volume de solvant initial). Â The filtrate recovered was compensated by adding a racemic salt of Bahma substantially equal to that of the crystals recovered at the previous crystallization. The filtrate was also compensated for solvent losses by adding solvent until reaching 40 mL (initial solvent volume).\n\nLe systÃ¨me a ensuite Ã©tÃ© chauffÃ© de nouveau Ã TB oÃ¹ une nouvelle suspension a Ã©tÃ© obtenue. AprÃ¨s une demi-heure de mise Ã l'Ã©quilibre Ã cette tempÃ©rature, le mÃªme programme de refroidissement a Ã©tÃ© appliquÃ© Ã la fin duquel une nouvelle filtration donne l'Ã©nantiomÃ¨re opposÃ© au prÃ©cÃ©dent. Le recyclage successif permet de rÃ©cupÃ©rer le mÃªme Ã©nantiomÃ¨re que celui de dÃ©part suite aux cristallisations impaires, alors que l'autre Ã©nantiomÃ¨re est systÃ©matiquement rÃ©cupÃ©rÃ© pour toutes les cristallisations paires. The system was then reheated to T B where a new suspension was obtained. After half an hour of equilibration at this temperature, the same cooling program was applied at the end of which a new filtration gives the enantiomer opposite to the previous one. The successive recycling makes it possible to recover the same enantiomer as the starting one following the odd crystallizations, while the other enantiomer is systematically recovered for all the even crystallizations.\n\nPar recyclage successif, il est alors possible de dÃ©doubler de faÃ§on prÃ©parative les deux Ã©nantiomÃ¨res d'un mÃ©lange racÃ©mique. Â By successive recycling, it is then possible to prepare the two enantiomers of a racemic mixture in a preparative manner.\n\nEXEMPLES EXAMPLES\n\nExemple 1 : PrÃ©paration et CaractÃ©risation de sels de Bahma Â Example 1 Preparation and Characterization of Bahma Salts\n\nLes sels de Bahma (racÃ©mique ou Ã©nantiopur) utilisÃ©s dans le procÃ©dÃ© de la prÃ©sente invention ont Ã©tÃ© prÃ©parÃ©s par Ã©vaporation d'une suspension de baclofÃ¨ne (racÃ©mique ou Ã©nantiopur) et d'acide malÃ©ique (mÃ©lange de stÅchiomÃ©trie 1 : 1 ) dans de l'acÃ©tone. Â The Bahma salts (racemic or enantiopur) used in the process of the present invention were prepared by evaporation of a suspension of baclofen (racemic or enantiopur) and maleic acid (mixture of stoichiometry 1: 1) in acetone.\n\nLes monocristaux de sel de Bahma pour les analyses de diffraction des rayons X ont Ã©tÃ© obtenus par dissolution de 50mg de sel racÃ©mique de Bahma dans un volume donnÃ© de solvant : eau , mÃ©thanol ou encore azÃ©otrope eau/n-propanol (pour atteindre une solution homogÃ¨ne, le mÃ©lange peut Ãªtre chauffÃ©). AprÃ¨s dissolution des solides, une tempÃ©rature peut Ãªtre imposÃ©e Ã la solution ou celle-ci est laissÃ©e Ã tempÃ©rature ambiante (environ 20Â°C). Les cristaux de sel fortement enrichis de Bahma se forment par Ã©vaporation du solvant ou mÃ©lange de solvant aprÃ¨s quelques jours pour les Ã©vaporations les plus lentes, des monocristaux ont ainsi Ã©tÃ© obtenus par Ã©vaporation de solutions laissÃ©es Ã 20, 50 et 70Â°C. Bahma salt single crystals for X-ray diffraction analyzes were obtained by dissolving 50 mg of racemic Bahma salt in a given volume of solvent: water, methanol or azeotrope water / n-propanol (to reach a homogeneous solution , the mixture can be heated). After dissolution of the solids, a temperature may be imposed on the solution or it is left at room temperature (about 20 Â° C). Salt crystals highly enriched with Bahma are formed by evaporation of the solvent or solvent mixture after a few days for the slowest evaporations, monocrystals were obtained by evaporation of solutions left at 20, 50 and 70 Â° C.\n\nCes monocristaux ont Ã©tÃ© Ã©tudiÃ©s par diffraction des rayons X pour en dÃ©terminer la structure complÃ¨te. Les donnÃ©es cristallographiques d'un monocristal obtenu Ã 20Â°C sont reportÃ©es dans le tableau 1. Â These single crystals were studied by X-ray diffraction to determine the complete structure. The crystallographic data of a monocrystal obtained at 20 Â° C are reported in Table 1.\n\nRi =â(||Fo|-|Fc||)/â |F0| Ri = Î£ (|| Fo | - | Fc ||) / Î£ | F 0 |\n\nwR(F2) = [â [ w (F0 2 - Fc 2) 2] /â [ w (F0 2)2 ] ]1 wR (F 2 ) = [Î£ [w (F 0 2 - F c 2 ) 2 ] / Î£ [w (F 0 2 ) 2 ]] 1\n\nTableau 1 Table 1\n\nLe groupe d'espace, le nombre de molÃ©cules dans l'unitÃ© asymÃ©trique, l'absence de dÃ©sordre et la valeur du paramÃ¨tre de Flack indiquent une discrimination chirale quasi-totale Ã l'Ã©tat solide Ã tempÃ©rature ambiante. Ces observations ont Ã©tÃ© corrÃ©lÃ©es par un comportement identique jusqu'Ã au moins 70Â°C. The space group, the number of molecules in the asymmetric unit, the absence of disorder and the value of the Flack parameter indicate an almost total chiral discrimination in the solid state at room temperature. These observations were correlated by identical behavior up to at least 70 Â° C.\n\nLe Tableau 2 ci-dessous montre les coordonnÃ©es rÃ©duites des atomes sauf hydrogÃ¨ne (x104) et le facteur d'agitation isotrope UÃ©q (A2 x 103). Table 2 below shows the reduced coordinates of the atoms except hydrogen (x10 4 ) and the isotropic stirring factor U eq (A 2 x 10 3 ).\n\nAtome X y z uÃ©q Atom X yzu eq\n\nC(1) -5631(3) 8817(1) -938(2) 33(1)Â C (1) -5631 (3) 8817 (1) -938 (2) 33 (1)\n\nC(2) -3549(3) 9419(1) -1112(2) 35(1)C (2) -3549 (3) 9419 (1) -1112 (2) 35 (1)\n\nC(3) -3199(3) 10379(1) -272(2) 31(1)C (3) -3199 (3) 10379 (1) -272 (2) 31 (1)\n\nC(4) -1434(3) 10998(1) -828(2) 36(1)C (4) -1434 (3) 10998 (1) -828 (2) 36 (1)\n\nC(5) -2316(3) 10237(1) 1357(2) 30(1)C (5) -2316 (3) 10237 (1) 1357 (2) 30 (1)\n\nC(6) -80(3) 9806(1) 2015(2) 37(1)C (6) -80 (3) 9806 (1) 2015 (2) 37 (1)\n\nC(7) 739(3) 9687(1) 3512(2) 39(1)C (7) 739 (3) 9687 (1) 3512 (2) 39 (1)\n\nC(8) -725(4) 9994(1) 4340(2) 39(1)C (8) -725 (4) 9994 (1) 4340 (2) 39 (1)\n\nC(9) -2951(3) 10412(1) 3718(2) 41(1)C (9) -2951 (3) 10412 (1) 3718 (2) 41 (1)\n\nC(10) -3730(3) 10535(1) 2229(2) 35(1)C (10) -3730 (3) 10535 (1) 2229 (2) 35 (1)\n\nCl(1) 289(1) 9851(1) 6215(1) 58(1)Cl (1) 289 (1) 9851 (1) 6215 (1) 58 (1)\n\nN(1) -1225(3) 12006(1) -269(2) 38(1) 0(1) -7139(2) 9107(1) -380(2) 46(1) N (1) -1225 (3) 12006 (1) -269 (2) 38 (1) 0 (1) -7139 (2) 9107 (1) -380 (2) 46 (1)\n\n0(2) -5825(2) 7935(1) -1485(1) 39(1)Â 0 (2) -5825 (2) 7935 (1) -1485 (1) 39 (1)\n\nC(1A) 2665(3) 2546(1) 3835(2) 35(1)C (1A) 2665 (3) 2546 (1) 3835 (2) 35 (1)\n\n0(1 A) 2173(2) 2425(1) 2502(1) 41(1)0 (1 A) 2173 (2) 2425 (1) 2502 (1) 41 (1)\n\n0(2A) 4794(3) 2762(2) 4591(2) 67(1)0 (2A) 4794 (3) 2762 (2) 4591 (2) 67 (1)\n\nC(2A) 683(3) 2437(1) 4532(2) 35(1)C (2A) 683 (3) 2437 (1) 4532 (2) 35 (1)\n\nC(3A) 787(3) 2427(2) 5927(2) 37(1)C (3A) 787 (3) 2427 (2) 5927 (2) 37 (1)\n\nC(4A) 2891(4) 2502(2) 7252(2) 40(1)C (4A) 2891 (4) 2502 (2) 7252 (2) 40 (1)\n\n0(3A) 5022(3) 2668(2) 7127(2) 62(1)0 (3A) 5022 (3) 2668 (2) 7127 (2) 62 (1)\n\n0(4A) 2565(3) 2399(1) 8443(2) 60(1) 0 (4A) 2565 (3) 2399 (1) 8443 (2) 60 (1)\n\nTableau 2 Â Table 2\n\nLe Tableau 3 ci-dessous montre les coordonnÃ©es rÃ©duites des atomes d'hydrogÃ¨ne (x104) et le facteur d'agitation isotrope UÃ©q (A2 x 103). Table 3 below shows the reduced coordinates of the hydrogen atoms (x10 4 ) and the isotropic stirring factor U eq (A 2 x 10 3 ).\n\nTableau 3 Le tableau 4 ci-dessous montre la position et l'intensitÃ© calculÃ©es et mesurÃ©es des pics caractÃ©ristiques DRX du sel racÃ©mique de Bahma. Les diffractogrammes DRX correspondants sont reprÃ©sentÃ©s Ã la Figure 6. Â Table 3 Table 4 below shows the calculated and measured position and intensity of the characteristic XRD peaks of the racemic salt of Bahma. The corresponding XRD diffractograms are shown in Figure 6.\n\nIndices de Miller Bahma calculÃ© Bahma mesurÃ© Miller Bahma indices calculated Bahma measured\n\nIntensitÃ© IntensitÃ© h k I 26/deg d/Ã l/rel. 26/deg d/Ã Intensity Intensity h k I 26 / deg d / Ã l / rel. 26 / deg d /\n\n(coups) (l/lo %)Â (hits) (l / lo%)\n\n0 0 1 9.59 9.22 2.41 9.58 9.223 344 1.80 0 1 9.59 9.22 2.41 9.58 9.223 344 1.8\n\n0 1 1 11.54 7.66 2.72 11.51 7.679 1116 5.80 1 1 11.54 7.66 2.72 11.51 7.679 1116 5.8\n\n0 2 0 12.83 6.89 5.77 12.81 6.904 2266 11.80 2 0 12.83 6.89 5.77 12.81 6.904 2266 11.8\n\n0 2 1 16.04 5.52 4.96 16.03 5.525 2047 10.60 2 1 16.04 5.52 4.96 16.03 5.525 2047 10.6\n\n1 0 0 16.12 5.49 5.4 1 0 0 16.12 5.49 5.4\n\n-1 0 1 16.24 5.45 54.44 16.21 5.462 8893 46.2Â -1 0 1 16.24 5.45 54.44 16.21 5.462 8893 46.2\n\n1 1 0 17.36 5.1 33.95 17.35 5.108 6557 341 1 0 17.36 5.1 33.95 17.35 5.108 6557 34\n\n-1 1 1 17.47 5.07 19.97 17.45 5.078 3944 20.5 0 1 2 20.3 4.37 6.49 20.28 4.375 1874 9.7-1 1 1 17.47 5.07 19.97 17.45 5.078 3944 20.5 0 1 2 20.3 4.37 6.49 20.28 4.375 1874 9.7\n\n1 2 0 20.66 4.3 51.05 20.64 4.3 8915 46.31 2 0 20.66 4.3 51.05 20.64 4.3 8915 46.3\n\n-1 2 1 20.75 4.28 44.13 20.7 4.288 8204 42.6-1 2 1 20.75 4.28 44.13 20.7 4.288 8204 42.6\n\n1 0 1 21.04 4.22 3.14 21.02 4.224 1696 8.81 0 1 21.04 4.22 3.14 21.02 4.224 1696 8.8\n\n3 1 21.59 4.11 22.72 21.56 4.1 19 5218 27.13 1 21.59 4.11 22.72 21.56 4.1 19 5218 27.1\n\n1 1 1 22.02 4.03 29.17 21.99 4.039 6216 32.31 1 1 22.02 4.03 29.17 21.99 4.039 6216 32.3\n\n-1 1 2 22.28 3.99 17.94 22.24 3.993 2895 15-1 1 2 22.28 3.99 17.94 22.24 3.993 2895 15\n\n2 2 23.2 3.83 2.46 23.16 3.837 1381 7.22 2 23.2 3.83 2.46 23.16 3.837 1381 7.2\n\n1 2 1 24.72 3.6 14.87 24.69 3.603 3047 15.81 2 1 24.72 3.6 14.87 24.69 3.603 3047 15.8\n\n-1 2 2 24.95 3.57 13.08 24.92 3.57 2218 1 1.5-1 2 2 24.95 3.57 13.08 24.92 3.57 2218 1 1.5\n\n1 3 0 25.24 3.53 78.2 25.22 3.528 9331 48.41 3 0 25.24 3.53 78.2 25.22 3.528 9331 48.4\n\n-1 3 1 25.32 3.51 7.46 -1 3 1 25.32 3.51 7.46\n\n0 4 0 25.82 3.45 100 25.79 3.452 19184 100Â 0 4 0 25.82 3.45 100 25.79 3.452 19184 100\n\n0 3 2 27.38 3.25 11.56 27.35 3.258 2470 12.80 3 2 27.38 3.25 11.56 27.35 3.258 2470 12.8\n\n0 4 1 27.61 3.23 34.09 27.57 3.233 5707 29.60 4 1 27.61 3.23 34.09 27.57 3.233 5707 29.6\n\n1 0 2 28.6 3.12 2.89 28.55 3.124 1238 6.41 0 2 28.6 3.12 2.89 28.55 3.124 1238 6.4\n\n1 3 1 28.7 3.11 6.3 28.68 3.1 1 1618 8.41 3 1 28.7 3.11 6.3 28.68 3.1 1 1618 8.4\n\n-1 3 2 28.9 3.09 4.41 28.87 3.09 1396 7.2-1 3 2 28.9 3.09 4.41 28.87 3.09 1396 7.2\n\n-1 0 3 28.93 3.08 2.51 -1 0 3 28.93 3.08 2.51\n\n1 1 2 29.34 3.04 27.72 29.29 3.047 51 13 26.5Â 1 1 2 29.34 3.04 27.72 29.29 3.047 51 13 26.5\n\n-1 1 3 29.66 3.01 4.39 -1 1 3 29.66 3.01 4.39\n\n0 1 3 29.77 3 17.51 29.71 3.005 3125 16.2 Â 0 1 3 29.77 3 17.51 29.71 3.005 3125 16.2\n\nTableau 4 Table 4\n\nExemple 2 : DÃ©doublement dans le mÃ©lange azÃ©otropique n-propanol/eau par cristallisation prÃ©fÃ©rentielle autoensemencÃ©e Example 2: Duplication in the azeotropic n-propanol / water mixture by preferential self-priming crystallization\n\nLa solubilitÃ© du sel racÃ©mique de Bahma Ã diffÃ©rentes tempÃ©ratures a Ã©tÃ© dÃ©terminÃ©e dans le mÃ©lange azÃ©otropique n-propanol/eau (p =0,870 g.mL\" ). Les valeurs calculÃ©es sont introduites dans le tableau ci-dessous. The solubility of the racemic salt Bahma at different temperatures was determined in the azeotropic mixture of n-propanol / water (p = 0.870 g.mL \"). The calculated values are introduced into the table below.\n\nPlusieurs entraÃ®nements ont Ã©tÃ© rÃ©alisÃ©s dans ce solvant Ã partir d'une solution racÃ©mique saturÃ©e Ã 50Â°C en suivant le dispositif expÃ©rimental dÃ©crit prÃ©cÃ©demment. Â Several operations were carried out in this solvent from a saturated racemic solution at 50 Â° C following the experimental device described above.\n\nSystÃ¨me 40m L saturÃ©s Ã 50Â°C (1.7583g de Bahma rac. dans 34.796g de Initial: Solvant) et 0.2505g de Bahma-100%ee System 40m L saturated at 50 Â° C (1.7583g of Bahma rac in 34.796g of Initial: Solvent) and 0.2505g of Bahma-100% ee\n\nSolution RÃ©coltes Brutes Â Raw Harvest Solution\n\nTempÃ©rature Temps Â Temperature Time\n\n(Â°C) (min) Masse ee Â (Â° C) (min) Mass ee\n\nee (%) Â ee (%)\n\n(g) (%) Â (boy Wut) (%)\n\n53 0 -4.71 Â 53 0 -4.71\n\n50 6 -4.44 Â 50 6 -4.44\n\n45 16 -0.40 Â 45 16 -0.40\n\nEssai 1 40 26 4.54 Â Test 1 40 26 4.54\n\n35 36 1 1.69 Â 35 36 1 1.69\n\n32.5 41 15.30 Â 32.5 41 15.30\n\n30 46 19.92 0.6682 g -91.08 Â 30 46 19.92 0.6682 g -91.08\n\nCompensation 0.6895g de Bahma rac. Â Compensation 0.6895g of Bahma rac.\n\n4h Ã 53Â°C Â 4h at 53 Â° C\n\net 2mL de Solvant Â and 2mL Solvent\n\n53 0 6.43 Â 53 0 6.43\n\nEssai 2 35 36 -9.89 Â Test 2 35 36 -9.89\n\n30 46 -18.08 0.6587 g +84.29 Â 30 46 -18.08 0.6587 g +84.29\n\nCompensation 0.6718g de Bahma rac. Â Compensation 0.6718g of Bahma rac.\n\n12h Ã 53Â°C Â 12h to 53 Â° C\n\net 2 mL de Solvant Â and 2 mL of Solvent\n\n53 0 -5.47 Â 53 0 -5.47\n\nEssai 3 35 36 -3.37 Â Test 3 35 36 -3.37\n\n30 46 10.02 0.4971 g -91.03 Â 30 46 10.02 0.4971 g -91.03\n\nCompensation 0.4955g de Bahma rac. Â Compensation 0.4955g of Bahma rac.\n\n2h Ã 53Â°C Â 2h at 53 Â° C\n\net 2mL de Solvant Â and 2mL Solvent\n\n53 0 5.14 Â 53 0 5.14\n\nEssai 4 35 36 -2.38 Â Test 4 35 36 -2.38\n\n30 46 -1 1.27 0.4156 g +82.72 Â 30 46 -1 1.27 0.4156 g +82.72\n\n1 h Ã 53Â°C Compensation 0.4153g de Bahma rac. Â 1 h at 53 Â° C Compensation 0.4153g of Bahma rac.\n\n53 0 -3.07 Â 53 0 -3.07\n\nEssai 5 35 36 12.84 Â Test 5 35 36 12.84\n\n30 46 20.93 0.5608 g -93.78 Â 30 46 20.93 0.5608 g -93.78\n\nCompensation 0.555g de Bahma rac. Â Compensation 0.555g of Bahma rac.\n\n30 min Ã 53Â°C Â 30 min at 53 Â° C\n\net 1.5mL de Solvant Â and 1.5mL of Solvent\n\n53 0 9.76 Â 53 0 9.76\n\nEssai 6 35 36 -5.35 Â Test 6 35 36 -5.35\n\n30 46 -13.76 0.5339 g +96.59 SystÃ¨me 40m L saturÃ©s at 50Â°C (1.7583g de Bahma rac. dans 34.796g de Initial: Solvant) et 0.2445g de Bahma-100%ee 30 46 -13.76 0.5339 g + 96.59 System 40m L saturated at 50 Â° C (1.7583g of Bahma rac in 34.796g of Initial: Solvent) and 0.2445g of Bahma-100% ee\n\nSolution RÃ©coltes brutesÂ Crude Harvest Solution\n\nTempÃ©rature Temps Temperature Time\n\n(Â°C) (min) Masse ee ee (%) Â (Â° C) (min) Mass ee ee (%)\n\n(g) (%)Â (boy Wut) (%)\n\n53 0 -1 1.88 53 0 -1 1.88\n\nEssai 1 35 36 -3.47 Â Test 1 35 36 -3.47\n\n30 46 9.75 0.5012 g -94.04% Â 30 46 9.75 0.5012 g -94.04%\n\nCompensation 0.5120g de Bahma rac.Â Compensation 0.5120g of Bahma rac.\n\n60min Ã 53Â°C 60min to 53 Â° C\n\net 1.2ml_ de Solvant Â and 1.2ml_ of Solvent\n\n53 0 5.70 Â 53 0 5.70\n\nEssai 2 35 36 -9.90 Â Test 2 35 36 -9.90\n\n30 46 -17.87 0.4679 g +84.61% Â 30 46 -17.87 0.4679 g + 84.61%\n\nCompensation 0.4621 g de Bahma rac.Â Compensation 0.4621 g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 1ml_ de Solvant Â and 1ml_ of Solvent\n\n53 0 -8.86 Â 53 0 -8.86\n\nEssai 3 35 36 6.62 Â Test 3 35 36 6.62\n\n30 46 15.26 0.5496 g -95.07% Â 30 46 15.26 0.5496 g -95.07%\n\nCompensation 0.5469g de BahmaÂ Compensation 0.5469g of Bahma\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\nrac.et 1.5ml_ de Solvant Â rac.et 1.5ml_ of Solvent\n\n53 0 8.16 Â 53 0 8.16\n\nEssai 4 35 36 -8.64 Â Test 4 35 36 -8.64\n\n30 46 -17.34 0.6465g +92.52% Â 30 46 -17.34 0.6465g + 92.52%\n\nCompensation 0.5122g de Bahma rac.Â Compensation 0.5122g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 1.5ml_ de Solvant Â and 1.5ml_ of Solvent\n\n53 0 -8.02 Â 53 0 -8.02\n\nEssai 5 35 36 9.69 Â Test 5 35 36 9.69\n\n30 46 19.47 0.6463g -88.51% Â 30 46 19.47 0.6463g -88.51%\n\nCompensation 0.5136g de Bahma rac.Â Compensation 0.5136g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 1.75ml_ de Solvant Â and 1.75ml_ of Solvent\n\n53 0 1 1.09 Â 53 0 1 1.09\n\nEssai 6 35 36 -5.15 Â Test 6 35 36 -5.15\n\n30 46 -17.59 0.6124g +91.71% Â 30 46 -17.59 0.6124g + 91.71%\n\nCompensation 0.4975g de Bahma rac.Â Compensation 0.4975g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 1.5ml_ de Solvant Â and 1.5ml_ of Solvent\n\n53 0 -12.35 Â 53 0 -12.35\n\nEssai 7 35 36 -2.47 Â Test 7 35 36 -2.47\n\n30 46 12.65 0.5378g -91.71% Â 30 46 12.65 0.5378g -91.71%\n\nCompensation 0.5306g de Bahma rac.Â Compensation 0.5306g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 2ml_ de Solvant Â and 2ml_ of Solvent\n\n53 0 7.46 Â 53 7.46\n\nEssai 8 35 36 -4.89 Â Test 8 35 36 -4.89\n\n30 46 -14.73 0.5254g +88.90% Â 30 46 -14.73 0.5254g + 88.90%\n\nCompensation 0.5238g de Bahma rac.Â Compensation 0.5238g of Bahma rac.\n\n30 min Ã 53Â°C 30 min at 53 Â° C\n\net 0.5ml_ de Solvant Â and 0.5ml_ of Solvent\n\n53 0 -6.25 Â 53 0 -6.25\n\nEssai 9 35 36 10.26 Â Test 9 35 36 10.26\n\n30 46 19.42 0.6444g -89.51% Compensation 0.5183g de Bahma rac. 30 46 19.42 0.6444g -89.51% Compensation 0.5183g of Bahma rac.\n\n30 min Ã 53Â°C Â 30 min at 53 Â° C\n\net 1ml_ de Solvant Â and 1ml_ of Solvent\n\n53 0 8.00 Â 53 0 8.00\n\nEssai 10 35 36 -7.59 Â Test 10 35 36 -7.59\n\n30 46 -16.49 0.7194g +87.05% Â 30 46 -16.49 0.7194g + 87.05%\n\nExemple 3 : DÃ©doublement dans de l'eau acidifiÃ©e par cristallisation prÃ©fÃ©rentielle autoensemencÃ©e Example 3: Duplication in acidified water by preferential self-priming crystallization\n\nLa solubilitÃ© du sel racÃ©mique de Bahma Ã diffÃ©rentes tempÃ©rature a Ã©tÃ© dÃ©terminÃ©e dans l'eau pure (p =1 g.mL 1), dans une solution aqueuse de HCI Ã 1 M (p =1 ,017 g.mL 1) et dans une solution aqueuse de HCI Ã 2M (p =1 ,030 g.mL\"1). Les valeurs calculÃ©es sont introduites dans le tableau ci-dessous. The solubility of the racemic Bahma salt at different temperatures was determined in pure water (p = 1 gmL 1 ), 1M aqueous HCl solution (p = 1, 017 gmL 1 ) and in 2M aqueous HCl solution (p = 1.030 g.mL -1 ) The calculated values are introduced in the table below.\n\nAinsi, l'utilisation d'une solution aqueuse acidifiÃ©e permet avantageusement d'augmenter la solubilitÃ© du sel racÃ©mique de Bahma ce qui permet d'amÃ©liorer la productivitÃ© de la cristallisation prÃ©fÃ©rentielle. Pour des concentr"
    }
}